Neonatal Jaundice
Neonatal jaundice is yellowish discoloration of the skin and sclera in newborns, typically occurring within the first 28 days of life, due to elevated unconjugated bilirubin from immature hepatic conjugation and increased red blood cell turnover.
Neonatal Jaundice (NNJ) — Definition, Epidemiology, Risk Factors, Anatomy & Physiology, Aetiology, Pathophysiology, Classification, and Clinical Features
Neonatal jaundice (NNJ) — also called icterus neonatorum — is the yellow discoloration of the skin, sclerae, and mucous membranes of a newborn infant caused by the accumulation of bilirubin in subcutaneous tissues. The word "jaundice" derives from the French jaune (yellow); "icterus" comes from the Greek ikteros (yellowness) [1][2].
- Jaundice becomes clinically visible when total serum bilirubin (TSB) reaches approximately 80–100 µmol/L (≈ 5 mg/dL) [3][4].
- It is important to distinguish from carotenaemia (yellow-orange skin from dietary carotene/lycopene), which spares the sclerae and mucous membranes [1][5].
Key Distinction — Conjugated vs Unconjugated
The single most important first step in evaluating any jaundiced neonate is to determine whether the hyperbilirubinaemia is unconjugated (indirect) or conjugated (direct). This dictates the entire downstream differential, investigation pathway, and urgency of referral. Conjugated hyperbilirubinaemia in a neonate is NEVER physiological and always warrants urgent investigation.
- Present in > 50% of term and > 80% of preterm infants within the first few days of life [3][4].
- More common in East Asians (including the Hong Kong Chinese population); Asian neonates tend to have higher peak bilirubin levels and a later peak (Day 4–5) compared with Caucasians (Day 2–4) [3][4][6].
- Approximately 60% of healthy full-term newborns develop visible jaundice in the first week [1].
- Severe hyperbilirubinaemia (TSB > 342 µmol/L / 20 mg/dL) occurs in a smaller subset but carries the risk of bilirubin-induced neurological dysfunction (BIND) [7].
Hong Kong Context
- G6PD deficiency is the most common enzymopathy worldwide and is highly prevalent in Southern Chinese (estimated 4–6% of males in Hong Kong) — this is a major contributor to pathological and severe NNJ locally [3][4].
- Universal neonatal cord-blood TSH screening is performed in Hong Kong for congenital hypothyroidism (incidence ~1:3,000 locally), which itself is a cause of prolonged unconjugated jaundice [8].
- Biliary atresia incidence is higher in East Asians (~1 in 5,000–8,000 live births in some Asian series vs ~1 in 15,000–18,000 in Western populations) [3].
Understanding risk factors is crucial because they determine who needs closer monitoring after birth.
| Category | Risk Factor | Mechanism / Rationale |
|---|---|---|
| Demographic | Male gender | Males have higher daily bilirubin production |
| Asian ethnicity | Likely genetic factors (UGT1A1 polymorphisms, higher G6PD deficiency prevalence) | |
| Maternal age ≥ 25 years | Association noted epidemiologically | |
| Gestational | Prematurity (especially GA 35–36 weeks, "late preterm") | Immature hepatic conjugation (low UDPGT activity), immature gut motility → ↑ enterohepatic circulation |
| Gestational diabetes mellitus (GDM) | Macrosomia → polycythaemia → ↑ haem turnover; also birth injury/bruising | |
| Haematological | Blood group incompatibility (ABO, Rh, Kell, Duffy) | Immune-mediated haemolysis → ↑ bilirubin load |
| G6PD deficiency | Oxidative stress → episodic/chronic haemolysis | |
| Hereditary spherocytosis / other RBC membrane/enzyme defects | ↑ RBC fragility → haemolysis | |
| Birth-related | Cephalhaematoma or significant bruising | Extravascular blood → breakdown of extravasated haem |
| Instrumental/traumatic delivery | Same mechanism as above | |
| Feeding | Exclusive breastfeeding | Suboptimal caloric intake in early days → dehydration, ↑ enterohepatic circulation; also breast milk factors (see below) |
| Inadequate feeding / excessive weight loss ( > 7–10% birth weight) | ↓ gut motility, ↓ stool output → ↑ enterohepatic circulation | |
| Other | Previous sibling with significant jaundice | Shared genetic/immune risk |
| High altitude | ↑ Erythropoiesis → polycythaemia | |
| East Asian genetic polymorphisms (UGT1A16, UGT1A128) | ↓ UDPGT expression/activity |
4. Anatomy, Physiology, and Normal Bilirubin Metabolism
Bilirubin is the end-product of haem catabolism. In newborns:
- ~75% comes from the breakdown of haemoglobin in senescent or haemolysed red blood cells (RBCs).
- ~25% comes from ineffective erythropoiesis and turnover of other haem-containing proteins (myoglobin, cytochromes, catalase).
Key enzymes and transporters: [3][4]
- Haem oxygenase — rate-limiting step; converts haem → biliverdin + CO + iron
- Biliverdin reductase — converts biliverdin → unconjugated bilirubin (UCB)
- Albumin — carrier protein in blood; UCB is water-insoluble so must be protein-bound
- Ligandin (glutathione-S-transferase) — intracellular carrier within hepatocyte
- UDP-glucuronosyltransferase (UDPGT / UGT1A1) — the key conjugation enzyme; adds glucuronic acid to make bilirubin water-soluble
- MRP2 (ABCC2) — canalicular transporter excreting conjugated bilirubin into bile
- β-glucuronidase — intestinal enzyme that deconjugates bilirubin → enables reabsorption (enterohepatic circulation)
Physiological jaundice arises from the convergence of THREE normal neonatal phenomena [4][6][7]:
| Factor | Adult vs Neonate | Explanation |
|---|---|---|
| ↑ Bilirubin production | Neonatal haematocrit is 50–60% (vs adult ~40%); fetal RBCs have a shorter lifespan (~70–90 days vs adult ~120 days) | More RBCs turning over faster = more haem = more bilirubin |
| ↓ Bilirubin clearance (conjugation) | Neonatal UDPGT activity is only ~1% of adult levels at birth, reaching adult levels by ~14 weeks | Immature enzyme → UCB accumulates because it cannot be conjugated efficiently |
| ↑ Enterohepatic circulation | Neonatal gut is relatively sterile (fewer bacteria to convert bilirubin to urobilinogen); gut motility is immature; feeding volumes are small in first days | Conjugated bilirubin sits in the gut longer → β-glucuronidase (abundant in neonatal intestinal brush border) deconjugates it → free UCB reabsorbed into portal circulation → returns to liver → net increase in serum UCB |
High Yield — Physiological Jaundice Definition Criteria
Physiological jaundice is a diagnosis of exclusion. It must satisfy ALL of the following:
- Appears after 24 hours of age (never in the first 24h — that is always pathological!)
- Peaks at Day 2–3 in Caucasians, Day 4–5 in Asians
- TSB does not exceed age-specific thresholds (roughly < 200–220 µmol/L in term)
- Rate of rise < 85 µmol/L/day (< 5 mg/dL/day)
- Resolves within 2 weeks (term) or 3 weeks (preterm)
- Unconjugated hyperbilirubinaemia only (conjugated bilirubin normal)
- Baby is well, feeding well, growing appropriately
- No evidence of haemolysis on blood film
Unlike adults (where TSB > 26 µmol/L is abnormal), neonatal bilirubin levels are interpreted against age-in-hours using a nomogram (e.g., Bhutani nomogram). There is no single "normal" TSB cutoff — it depends on postnatal age and risk zone.
- Term neonate: TSB typically peaks at ~100–170 µmol/L (6–10 mg/dL) around Day 3–5 [7].
- Preterm neonate: peaks may be higher (up to ~250 µmol/L) and later (Day 5–7) due to even more immature conjugation.
- Conjugated bilirubin should always be < 17.1 µmol/L (1 mg/dL) or < 15% of TSB — exceeding this defines conjugated hyperbilirubinaemia and is always pathological [3].
5. Aetiology and Classification
5.1 Temporal Classification (The Classic Framework)
This is the most clinically useful classification for neonatal jaundice and is the framework used in the GC lecture and the HKUMed paediatric curriculum [3][4][9]:
| Cause | Pathophysiology | Hong Kong Relevance |
|---|---|---|
| Haemolytic disorders — Blood group incompatibility (ABO, Rh, Kell, Duffy) | Maternal IgG antibodies cross placenta → attack fetal/neonatal RBCs → haemolysis → massive UCB production | ABO incompatibility (mother O, baby A or B) is the most common immune haemolytic cause. Rh disease is less common due to anti-D prophylaxis but still occurs. |
| RBC enzyme defects — especially G6PD deficiency | G6PD-deficient RBCs cannot regenerate NADPH → cannot reduce glutathione → oxidative damage → haemolysis (may be triggered by drugs, mothballs [naphthalene], fava beans, infection) | Very important in HK — ~4–6% of males; X-linked recessive but female carriers can be affected. All male neonates in HK are screened for G6PD deficiency at birth via the neonatal screening programme. |
| RBC membrane defects — hereditary spherocytosis (HS), hereditary elliptocytosis | Defective spectrin/ankyrin → spherical RBCs → trapped and destroyed in spleen → extravascular haemolysis | HS is the most common inherited membrane defect in Caucasians; less common but still seen in HK |
| Haemoglobinopathies — α-thalassaemia (Hb Bart's hydrops fetalis) | Absent α-globin chains → only γ₄ tetramers (Hb Bart's) → severe anaemia and haemolysis in utero | α-thalassaemia carrier rate is ~3–5% in Southern Chinese; homozygous α-thal major causes hydrops fetalis |
| Congenital infections (TORCH) | Infection → haemolysis + hepatitis → both ↑ production and ↓ clearance of bilirubin | CMV is the most common congenital infection globally |
Key teaching point: Jaundice within the first 24 hours of life is a RED FLAG — think haemolysis until proven otherwise. [3][4][9]
| Cause | Pathophysiology |
|---|---|
| Physiological jaundice | See Section 4.3 above — the triad of ↑ production, ↓ conjugation, ↑ enterohepatic circulation |
| Breastfeeding jaundice (distinct from breast milk jaundice) | Inadequate intake in the first few days → dehydration, ↓ stool output → ↑ enterohepatic circulation. This is essentially an exaggeration of physiological jaundice due to poor caloric intake. Improves with adequate feeding support. |
| Breast milk jaundice | Substances in breast milk (β-glucuronidase, lipase-generated free fatty acids, other unidentified factors) → inhibit UDPGT and/or promote enterohepatic circulation. Typically presents after Day 4–7, peaks at 2 weeks, and can persist for up to 12 weeks. The baby is well, thriving, and gaining weight. |
| Infection (especially UTI — a classic "hidden" cause of jaundice in neonates) | Sepsis/infection → ↓ hepatic function + haemolysis + ↑ enterohepatic circulation |
| Haemolytic disorders (same as above — can present in this window too) | As above |
| Internal haemorrhage (cephalhaematoma, subgaleal haemorrhage, IVH, adrenal haemorrhage) | Extravasated blood breaks down → large haem load → ↑ UCB production |
| Polycythaemia | Neonatal polycythaemia (e.g., IDM, twin-to-twin transfusion, delayed cord clamping, SGA) → more RBCs to break down → ↑ bilirubin |
| Crigler-Najjar syndrome | Type I: complete absence of UDPGT (AR) — severe, life-threatening; Type II: markedly reduced UDPGT — responds to phenobarbitone |
C. Prolonged / Persistent Jaundice ( > 2 weeks in term, > 3 weeks in preterm)
This is the group that demands fractionation of bilirubin (split into conjugated and unconjugated) to guide further workup.
| Cause | Key Points |
|---|---|
| Physiological / breastmilk jaundice (resolving) | Most common cause; baby well, gaining weight |
| Infection | UTI in particular; always check urinalysis and culture |
| Hypothyroidism | ↓ Thyroid hormone → ↓ UDPGT activity + ↓ gut motility → ↑ enterohepatic circulation. Picked up on newborn screening (cord blood TSH in HK). |
| Haemolytic disorders | Ongoing haemolysis from any cause listed above |
| High GI obstruction (e.g., pyloric stenosis) | Vomiting → dehydration + ↓ enteral intake → ↓ stool passage → ↑ enterohepatic circulation |
| Gilbert syndrome | Common (5% prevalence), usually not diagnosed until adolescence. UGT1A1 promoter polymorphism → mild ↓ conjugation. Rarely causes clinically significant neonatal jaundice alone but may compound other causes. |
| Cause | Key Points |
|---|---|
| Biliary atresia (BA) | The most important surgical cause to exclude — progressive obliterative cholangiopathy of intra- and extrahepatic bile ducts. Incidence ~1/5,000–15,000. Biliary atresia is the most common indication for paediatric liver transplantation. Presents with prolonged jaundice, pale/clay-coloured (acholic) stools, dark urine, hepatomegaly. Kasai portoenterostomy ideally before 60 days (and certainly before 12 weeks). |
| Choledochal cyst | Congenital cystic dilatation of bile ducts → obstruction → cholestasis |
| Neonatal hepatitis (idiopathic, viral, bacterial) | Aetiological agent often unknown; giant cell transformation on biopsy |
| Metabolic / IEM — galactosaemia, tyrosinaemia, citrin deficiency (NICCD), α₁-antitrypsin deficiency, cystic fibrosis, neonatal haemochromatosis | Each has a specific metabolic defect leading to hepatocyte dysfunction and/or cholestasis |
| Parenteral nutrition-associated cholestasis (PNAC) | Prolonged TPN ( > 2 weeks) → cholestasis via ↓ enteral stimulation of bile flow + lipid toxicity |
| Syndromic — Alagille syndrome (paucity of intrahepatic bile ducts + characteristic facies + cardiac/vertebral/ocular anomalies) | AR/AD depending on subtype |
| Inspissated bile syndrome | Concentrated bile plugging ducts, especially after haemolytic disease |
Exam Classic — Biliary Atresia vs Neonatal Hepatitis
A very common exam question. Both present with prolonged conjugated jaundice in a neonate. The key clinical clue is acholic (pale/clay-coloured) stools — persistently pale stools strongly suggest biliary atresia. In neonatal hepatitis, stools may be intermittently pale but often retain some pigment. The stool colour card is used in Hong Kong as a screening tool at the 1-month well-baby check. Never dismiss persistent pale stools in a jaundiced baby.
| Type | Bilirubin Fraction | Key Feature |
|---|---|---|
| Unconjugated (indirect) hyperbilirubinaemia | Predominantly UCB; conjugated bilirubin < 17.1 µmol/L and < 15% TSB | Yellow skin; normal urine colour; normal stool colour. Risk of kernicterus at very high levels. |
| Conjugated (direct) hyperbilirubinaemia | Conjugated bilirubin > 17.1 µmol/L (1 mg/dL) or > 15% of TSB | Yellow-greenish skin hue; tea-coloured (dark) urine; pale/acholic stools. Does NOT cause kernicterus but indicates serious hepatobiliary disease. |
| Feature | Physiological | Pathological |
|---|---|---|
| Onset | After 24 hours | Within first 24 hours (always pathological) or abnormally high/prolonged |
| TSB level | Within age-appropriate range | Exceeds age-specific phototherapy thresholds |
| Rate of rise | < 85 µmol/L/day (< 5 mg/dL/day) | > 85 µmol/L/day |
| Duration | Resolves by 2 weeks (term) / 3 weeks (preterm) | Persists beyond these cutoffs |
| Conjugated fraction | Normal (< 17.1 µmol/L) | Elevated (if conjugated → always pathological) |
| Clinical state | Baby well, feeding well | Unwell, poor feeding, hepatomegaly, pale stools, dark urine |
6. Pathophysiology — Specific Conditions in Detail
Already covered in Section 4.3. To summarise with a mnemonic:
Mnemonic: "PCE" — Production ↑, Conjugation ↓, Enterohepatic circulation ↑
These are frequently confused. They are two distinct entities:
| Breastfeeding Jaundice | Breast Milk Jaundice | |
|---|---|---|
| Timing | First 3–5 days | After Day 4–7, peaks at 2 weeks |
| Mechanism | Inadequate caloric intake → dehydration, ↓ stool frequency → ↑ enterohepatic circulation | Substances in breast milk (β-glucuronidase, lipase products, pregnanediol [older theory], epidermal growth factor) that inhibit UGT1A1 or ↑ intestinal bilirubin absorption |
| Baby's condition | May be dehydrated, losing weight excessively ( > 7–10% of birth weight) | Well, thriving, gaining weight |
| Management | Improve breastfeeding technique, increase feed frequency (8–12 times/day), consider supplementation if severe dehydration | Reassurance. Continue breastfeeding. Resolves spontaneously by 3 months. If diagnostic doubt, a 24–48h trial of formula leads to rapid ↓ in TSB (but this is rarely needed and interruption of breastfeeding is generally discouraged). |
| Type | Unconjugated | Unconjugated |
- ABO incompatibility: Mother is blood group O (has naturally occurring anti-A and anti-B IgG) → crosses placenta → attacks fetal A or B RBCs. Usually milder than Rh disease because A and B antigens are expressed on many tissue types (not just RBCs), so antibodies are "mopped up." However, can still cause significant jaundice.
- Rh (anti-D) incompatibility: Rh-negative mother sensitised (previous pregnancy, miscarriage, transfusion) → produces anti-D IgG → crosses placenta → severe haemolysis of Rh-positive fetal RBCs. Can cause hydrops fetalis in severe cases. Prevented by anti-D immunoglobulin prophylaxis.
- G6PD deficiency: X-linked recessive. The enzyme G6PD is essential for the hexose monophosphate shunt (pentose phosphate pathway), which generates NADPH → needed to regenerate reduced glutathione → protects RBCs from oxidative damage. Without it, oxidative stressors (infections, drugs like sulfonamides/antimalarials, naphthalene mothballs, fava beans) cause Heinz body formation (denatured haemoglobin precipitates) → bite cells/blister cells on smear → extravascular (and sometimes intravascular) haemolysis. In neonates, G6PD deficiency can cause severe NNJ even without an identifiable trigger, likely because neonatal RBCs are inherently more susceptible to oxidative stress.
This is the feared complication of unconjugated hyperbilirubinaemia. Conjugated bilirubin does NOT cause kernicterus — instead it signals hepatobiliary disease [3].
Mechanism:
- When UCB levels exceed the albumin-binding capacity, free (unbound) UCB circulates.
- Free UCB is lipophilic → crosses the blood-brain barrier (BBB).
- UCB is toxic to neurons, especially in the basal ganglia (globus pallidus, subthalamic nucleus), brainstem auditory nuclei, and hippocampus.
- Damage occurs via mitochondrial toxicity, excitotoxicity, oxidative stress, and apoptosis.
Factors that ↑ risk of BIND:
- Low serum albumin (preterm infants have lower albumin levels → lower binding capacity)
- Competitive binding to albumin by drugs (e.g., sulfonamides, ceftriaxone) or free fatty acids → displaces bilirubin
- Acidosis (↓ albumin-bilirubin binding affinity)
- Sepsis / infection (opens BBB, ↑ bilirubin production, ↓ albumin)
- Prematurity (immature BBB, lower albumin, greater susceptibility of developing brain)
- Hypoalbuminaemia from any cause
- Haemolysis (rapid ↑ in UCB can overwhelm binding capacity)
Clinical Presentation [3]:
| Stage | Syndrome | Features | Reversibility |
|---|---|---|---|
| Acute | Acute bilirubin encephalopathy (ABE) | Lethargy, hypotonia (early) → hypertonia, irritability, high-pitched cry, poor feeding (intermediate) → opisthotonos (severely arched back), retrocollis (arched neck), fever, seizures → coma and death | Potentially reversible with urgent treatment (exchange transfusion) |
| Chronic | Kernicterus (核黃疸) | Dystonic cerebral palsy (choreoathetoid movements), sensorineural hearing loss (SNHL), upward gaze palsy (due to damage to vertical gaze centres in midbrain), intellectual disability, enamel dysplasia / green-brown teeth discolouration | Irreversible |
The word "kernicterus" literally means "kern" (nucleus, German) + "icterus" (jaundice) — referring to yellow staining of the brain nuclei (especially basal ganglia) seen at autopsy.
Ceftriaxone & Neonates
Ceftriaxone is relatively contraindicated in neonates (especially those with jaundice or hypoalbuminaemia) because it displaces bilirubin from albumin, increasing free UCB and the risk of kernicterus. Use cefotaxime as the alternative third-generation cephalosporin in neonates.
Biliary atresia is the single most important cause of conjugated neonatal jaundice to identify early because it is surgically treatable, but outcomes are time-dependent. [3][4][9][10]
- Epidemiology: Incidence ~1/5,000–15,000 births; higher in East Asians
- Pathophysiology: Unknown aetiology (theories include viral trigger, immune-mediated injury, genetic susceptibility). Progressive inflammatory obliterative cholangiopathy affecting both extrahepatic and intrahepatic bile ducts → complete obstruction of bile flow → cholestasis → progressive hepatic fibrosis → biliary cirrhosis → liver failure and death by age 2 years if untreated [3].
- Two forms:
- Isolated (perinatal) form (~85%): normal anatomy initially, progressive destruction postnatally
- Syndromic (embryonic/fetal) form (~15%): associated with situs inversus, polysplenia, cardiac defects (laterality defects)
Clinical features of biliary atresia:
- Prolonged conjugated jaundice (the baby looked "well" initially)
- Acholic (clay/pale) stools — the hallmark finding; stool colour card screening used in HK
- Dark (tea-coloured) urine — conjugated bilirubin is water-soluble and spills into urine
- Hepatomegaly → progresses to hepatosplenomegaly (portal hypertension)
- Poor growth / failure to thrive — impaired bile flow → ↓ fat absorption → ↓ absorption of fat-soluble vitamins (A, D, E, K)
7. Clinical Features of Neonatal Jaundice
| Symptom | Pathophysiological Basis |
|---|---|
| Yellow discolouration of skin and eyes | Bilirubin deposition in subcutaneous tissues and sclerae. Visible when TSB > 80–100 µmol/L. |
| Poor feeding / lethargy | Early sign of bilirubin encephalopathy; also may indicate sepsis or dehydration exacerbating jaundice |
| High-pitched cry | Bilirubin neurotoxicity → brainstem irritation |
| Dark urine ("stains the nappy dark yellow/brown") | Indicates conjugated hyperbilirubinaemia — conjugated bilirubin is water-soluble → filtered by kidneys |
| Pale / clay-coloured stools | Absence of stercobilin due to obstructed biliary excretion (biliary atresia, choledochal cyst) |
| Excessive weight loss / poor weight gain | Inadequate feeding → dehydration → ↑ enterohepatic circulation (breastfeeding jaundice); or malabsorption in cholestatic disease |
Ask About Stool and Urine Colour!
Always ask about stool and urine colour in any jaundiced neonate. Dark urine + pale stools = conjugated hyperbilirubinaemia = urgent investigation needed. This is a question that is frequently tested in exams and commonly missed on the wards.
| Sign | Pathophysiological Basis |
|---|---|
| Jaundice — progresses cephalocaudally (Kramer's rule) | Bilirubin deposits in skin from head → trunk → extremities → palms/soles as levels rise. Face ≈ 85 µmol/L; mid-abdomen ≈ 256 µmol/L; soles ≈ 342 µmol/L [3] |
| Scleral icterus | Bilirubin has high affinity for elastin-rich scleral tissue; best assessed under natural light |
| Yellow-green hue | Suggests conjugated hyperbilirubinaemia (oxidised bilirubin → biliverdin gives greenish tinge) |
| Hepatomegaly | Haemolysis (extramedullary haematopoiesis), hepatitis, biliary obstruction |
| Splenomegaly | Haemolysis (extravascular destruction in spleen); portal hypertension (biliary atresia with cirrhosis) |
| Pallor | Anaemia from haemolysis |
| Petechiae / bruising | Congenital infection (TORCH); also ↓ vitamin K in cholestasis (↓ fat-soluble vitamin absorption) → coagulopathy |
| Cephalhaematoma / bruising / swelling | Extravascular blood → haem breakdown → ↑ UCB production |
| Hydrops fetalis (oedema, ascites, pleural effusion) | Severe anaemia from Rh disease or α-thalassaemia major → high-output cardiac failure |
| Hypotonia → hypertonia, opisthotonos, retrocollis | Acute bilirubin encephalopathy — bilirubin toxicity to basal ganglia and brainstem |
| Poor Moro reflex, absent sucking | Neurological depression from bilirubin toxicity |
| Dysmorphic features | May suggest syndromic cause (e.g., Alagille syndrome: triangular facies, posterior embryotoxon in eye; Down syndrome associated with polycythaemia) |
| Cataracts | Galactosaemia (a metabolic cause of conjugated jaundice) |
| Abnormal newborn reflexes / developmental concern | Congenital hypothyroidism, congenital infection |
- Always plot weight, length, and head circumference on age-appropriate growth charts.
- Poor weight gain may indicate:
- Inadequate feeding (breastfeeding jaundice)
- Malabsorption (cholestatic disease — ↓ bile salts → ↓ fat and fat-soluble vitamin absorption)
- Chronic haemolysis (↑ metabolic demand)
- Underlying metabolic disease
- Fat-soluble vitamin deficiencies (A, D, E, K) in cholestasis:
- Vitamin K: coagulopathy → bleeding (can present as haemorrhagic disease of the newborn)
- Vitamin D: rickets
- Vitamin A: poor night vision (unlikely to be detected in neonates)
- Vitamin E: haemolytic anaemia, neuromuscular dysfunction
- Neonatal jaundice is extremely common and often benign — parents need reassurance but also education about warning signs (increasing jaundice, poor feeding, lethargy, pale stools, dark urine).
- In Hong Kong, the stool colour card is given to all parents at discharge to monitor for acholic stools as a screen for biliary atresia.
- Cultural considerations: in Chinese culture, some traditional practices (e.g., keeping the baby wrapped up, avoiding sunlight) may delay recognition of jaundice.
- Consent/assent: In the neonatal period, all consent is obtained from parents/legal guardians. Explain phototherapy and (if needed) exchange transfusion clearly — parents often worry about "the light" and blood transfusion.
| Timing | Unconjugated Causes | Conjugated Causes |
|---|---|---|
| < 24 hours | Haemolytic disease (ABO, Rh, G6PD, HS, thal), congenital infection | — |
| 24h – 2 weeks | Physiological, breastfeeding jaundice, breast milk jaundice, infection (UTI), haemolysis, polycythaemia, cephalhaematoma, Crigler-Najjar | — (rare at this stage) |
| > 2 weeks (term) / > 3 weeks (preterm) | Breast milk jaundice, hypothyroidism, infection, haemolysis, pyloric stenosis, Gilbert syndrome | Biliary atresia, choledochal cyst, neonatal hepatitis, metabolic (galactosaemia, tyrosinaemia, citrin deficiency, α₁-AT deficiency, CF), PNAC, Alagille syndrome, neonatal haemochromatosis, inspissated bile |
High Yield Summary
- Neonatal jaundice is the most common clinical condition in neonates — > 50% term, > 80% preterm, higher in Asians.
- Physiological jaundice is due to ↑ bilirubin production (high Hct, short RBC lifespan), ↓ conjugation (immature UDPGT), and ↑ enterohepatic circulation (sterile gut, low feeding volumes). It appears after 24h, peaks Day 3–5, and resolves by 2 weeks.
- Jaundice < 24 hours = ALWAYS pathological → think haemolysis (ABO, Rh, G6PD).
- G6PD deficiency is the most important enzymopathy in Hong Kong Chinese males (~4–6%) — screened at birth.
- Prolonged jaundice ( > 2 weeks term / > 3 weeks preterm) → MUST fractionate bilirubin (split conjugated vs unconjugated).
- Conjugated hyperbilirubinaemia is NEVER physiological → urgent investigation to exclude biliary atresia (surgical emergency — Kasai before 60 days ideal).
- Biliary atresia is the most common indication for paediatric liver transplant. Clues: persistent acholic stools, dark urine, hepatomegaly.
- BIND / Kernicterus is caused by unconjugated bilirubin crossing the BBB → damages basal ganglia → acute: opisthotonos, seizures; chronic: dystonic CP, SNHL, upward gaze palsy.
- Ceftriaxone is avoided in jaundiced/hypoalbuminaemic neonates (displaces bilirubin from albumin).
- Stool colour card is used in Hong Kong to screen for biliary atresia at the 1-month check.
Active Recall - Neonatal Jaundice (Definition, Epidemiology, Pathophysiology, Clinical Features)
[1] Paediatrics in Review - Jaundice - Newborn to Age 2 Months.pdf (p. 1) [2] Ryan Ho Fundamentals.pdf (p. 295) [3] Adrian Lui Pediatrics Notes.pdf (pp. 46–48, 264) [4] MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 311) [5] Ryan Ho GI.pdf (p. 192) [6] Block C - A jaundiced child.pdf [7] Unconjugated hyperbilirubinemia in newborns ≥35 weeks of gestation: Etiology and pathogenesis - UpToDate.pdf (pp. 1, 9) [8] Block A - I am losing weight and sweating all the time: causes of severe weight loss; thyrotoxicosis; hypothyroidism.pdf (p. 41) [9] GC 146. A jaundiced child.pdf (pp. 31, 48) [10] Maksim Surgery Notes.pdf (p. 121)
Differential Diagnosis of Neonatal Jaundice
Before listing individual diseases, you must understand the logic of the differential. The single most important branch point in the entire approach to a jaundiced neonate is:
Is the hyperbilirubinaemia predominantly unconjugated (indirect) or conjugated (direct)? [3][9]
Why? Because the downstream differential, the urgency, and the feared complications are entirely different:
- Unconjugated → risk of kernicterus (neurotoxic); most causes are benign or haematological
- Conjugated → risk of progressive liver destruction (biliary atresia); NEVER physiological, always demands urgent workup [3][9][11]
The second branch point is timing of onset, which further narrows the differential.
2. Complete Differential Diagnosis — Organised by Timing and Bilirubin Type
| Cause | Category | Why It Causes Early Jaundice |
|---|---|---|
| ABO incompatibility | Immune haemolysis | Mother group O → has IgG anti-A/anti-B → crosses placenta → destroys fetal A/B RBCs → massive UCB load from birth [3][11][12] |
| Rh incompatibility | Immune haemolysis | Sensitised Rh-negative mother → anti-D IgG crosses placenta → severe haemolysis of Rh-positive fetal RBCs; can cause hydrops fetalis [3][12] |
| Other blood group incompatibility (Kell, Duffy, Kidd) | Immune haemolysis | Same mechanism — maternal alloantibodies attack fetal RBCs |
| G6PD deficiency | RBC enzyme defect | Neonatal RBCs already vulnerable to oxidative stress; in severe cases jaundice begins < 24h even without a clear trigger [3][11] |
| Hereditary spherocytosis / elliptocytosis | RBC membrane defect | Abnormal cytoskeleton → splenic trapping and destruction → extravascular haemolysis from birth [14] |
| Pyruvate kinase deficiency | RBC enzyme defect | Impaired glycolysis → ATP depletion → rigid RBCs → haemolysis |
| α-thalassaemia major (Hb Bart's hydrops) | Haemoglobinopathy | No α-globin → only γ₄ tetramers → severe anaemia/haemolysis in utero and from birth |
| Congenital infection (TORCH — CMV, toxoplasma, rubella, syphilis, HSV) | Infection | Direct hepatocyte damage (conjugated component) AND haemolysis → mixed picture; often < 24h [3][11] |
High Yield — ABO vs Rh Incompatibility in the Neonatal Context
ABO incompatibility is the most common cause of immune haemolytic disease in neonates [12]. Key features distinguishing it from Rh disease:
- ABO: Can occur in first pregnancy (mother already has naturally occurring anti-A/B IgG). Usually milder because A/B antigens are expressed on many tissue types → antibodies are "mopped up." Direct Coombs test may be weakly positive or negative.
- Rh: Typically requires prior sensitisation (previous pregnancy/transfusion). More severe. Direct Coombs test is strongly positive. Hydrops fetalis possible.
| Cause | Category | Key Distinguishing Feature |
|---|---|---|
| Physiological jaundice | Normal variant | Diagnosis of exclusion [3]. Onset Day 2–3, peaks Day 4–5 (Asians), resolves by 2 weeks. Baby well, feeding well. UCB only, no haemolysis on film, normal hepatic enzymes [4][6] |
| Breastfeeding jaundice | Feeding-related | Inadequate intake → dehydration → ↓ stool frequency → ↑ enterohepatic circulation. Baby may be losing > 7–10% birth weight. Improves with adequate feeding [3][11][15] |
| Breast milk jaundice | Feeding-related | Substances in breast milk (β-glucuronidase, lipase products, EGF) → inhibit UDPGT / ↑ enterohepatic circulation. Baby is well and thriving — this is the key distinction from breastfeeding jaundice. Onset after Day 4–7, can persist weeks [3][11][15] |
| Infection (especially UTI) | Infection | A "hidden" but classic cause — always check urinalysis and urine culture in any neonate with unexplained jaundice [3][11]. Mechanism: sepsis → ↓ hepatic function + haemolysis + ↑ enterohepatic circulation |
| Cephalhaematoma / significant bruising | Extravascular haemorrhage | Extravasated blood → haem breakdown over days → ↑ UCB production [4][6] |
| Polycythaemia | ↑ RBC mass | More RBCs = more haem to metabolise. Causes: infant of diabetic mother (IDM), twin-to-twin transfusion syndrome, delayed cord clamping, SGA [3][11] |
| Crigler-Najjar syndrome | Congenital conjugation defect | Type I: absent UDPGT → severe UCB, risk of kernicterus, fatal without treatment; Type II: markedly reduced UDPGT → responds to phenobarbitone [3][13][16] |
| Haemolytic disorders (as in 2A) | Haemolysis | May present in this window if milder or detected later |
Important questions to ask at this stage [11]:
- Age of onset ( < 48h, D3–7, after D7)?
- Urine and stool colour (dark urine/pale stool → conjugated)?
- Fever (infection)?
- Weight change and urine output (dehydration / breastfeeding failure)?
- Maternal blood group?
- Birth history: gestation, cord blood screening (ABO/G6PD in HK), mode of delivery, bruising?
- Feeding: breast vs formula, frequency, volume?
- Family history: G6PD, jaundice, anaemia, splenectomy, liver disease?
2C. Prolonged / Persistent Jaundice ( > 2 weeks term, > 3 weeks preterm)
This is where the fractionation of bilirubin becomes absolutely critical because the differential splits completely.
| Cause | Why Prolonged? | Key Clinical Clue |
|---|---|---|
| Breast milk jaundice | Ongoing inhibition of conjugation by breast milk components; can last up to 12 weeks | Baby well, thriving, gaining weight — most common cause of prolonged unconjugated jaundice [3][11] |
| Hypothyroidism | ↓ Thyroid hormone → ↓ UDPGT activity + ↓ gut motility → ↑ enterohepatic circulation | Should be picked up on neonatal cord blood TSH screening (done in HK). Other clues: prolonged jaundice, constipation, macroglossia, umbilical hernia, poor feeding, hypotonia [3][8] |
| Infection | UTI, late-onset sepsis → ongoing haemolysis + hepatic dysfunction | Fever, irritability, poor feeding; UTI may be occult — must check urine [3][11] |
| Ongoing haemolytic disorders | Continued RBC destruction → persistent UCB load | Anaemia, reticulocytosis, splenomegaly |
| High GI obstruction (e.g., pyloric stenosis) | Vomiting → dehydration + ↓ enteral intake → ↓ stool passage → ↑ enterohepatic circulation | Typically presents at 2–8 weeks with projectile, non-bilious vomiting, visible peristalsis, palpable olive [3] |
| Gilbert syndrome | ↓ UGT1A1 expression (promoter polymorphism, AD/AR) | Usually not clinically apparent until adolescence, but can compound other causes of NNJ in neonatal period. Mild isolated UCB elevation ( < 100 µmol/L) [13][16] |
| Cause | Mechanism | Key Features / HK Relevance |
|---|---|---|
| Biliary atresia (BA) | Progressive obliterative cholangiopathy → complete obstruction → fibrosis → cirrhosis → death < 2 years if untreated [3][10] | Most important diagnosis to exclude in prolonged conjugated jaundice. Acholic stools, dark urine, hepatomegaly. Biliary atresia is the most common indication for paediatric liver transplant [3]. Kasai portoenterostomy ideally before 60 days [10] |
| Choledochal cyst | Congenital cystic/fusiform dilatation of bile ducts → obstruction → cholestasis [10] | May mimic BA; diagnosed on USG/MRCP. Treatment: complete cyst excision + Roux-en-Y hepaticojejunostomy [10] |
| Neonatal hepatitis syndrome | Idiopathic (most common) or secondary to viral/bacterial infection → hepatocyte injury → giant cell transformation → cholestasis [3][15] | Aetiological agent unknown in majority; stools may be intermittently pale (cf. persistently pale in BA) |
| Metabolic / IEM: | ||
| — Galactosaemia | Deficiency of galactose-1-phosphate uridylyltransferase → toxic galactose-1-phosphate accumulates in liver, brain, kidneys | Vomiting, poor feeding, hepatomegaly, cataracts, E. coli sepsis. Reducing substances in urine. |
| — Tyrosinaemia type 1 | Fumarylacetoacetate hydrolase deficiency → accumulation of toxic metabolites → hepatocyte necrosis | Liver failure, renal tubular dysfunction, cabbage-like odour |
| — Citrin deficiency (NICCD) | Citrin (mitochondrial aspartate-glutamate carrier) defect → impaired urea cycle and gluconeogenesis in liver | Important in East Asian populations (common in Japanese and Chinese) — fatty liver, cholestasis, low birth weight |
| — α₁-antitrypsin deficiency | Misfolded α₁-AT protein accumulates in hepatocyte ER → hepatocyte injury → cholestasis/cirrhosis | PiZZ phenotype; also causes emphysema in adults |
| — Cystic fibrosis | Inspissated secretions block intrahepatic bile ducts → cholestasis; also pancreatic insufficiency | Rare in Chinese (much more common in Caucasians); meconium ileus, steatorrhoea |
| — Neonatal haemochromatosis (gestational alloimmune liver disease, GALD) | Maternal alloantibodies against fetal hepatocyte antigens → complement-mediated hepatocyte destruction in utero → severe liver failure + extrahepatic siderosis | Very severe — presents as neonatal liver failure; ferritin massively elevated; lip biopsy shows siderosis of minor salivary glands |
| Parenteral nutrition-associated cholestasis (PNAC) | Prolonged TPN → ↓ enteral stimulation → ↓ bile flow; lipid component directly toxic to hepatocytes | Preterm infants on prolonged TPN ( > 2 weeks); incidence declining with fish-oil based lipid emulsions [15] |
| Alagille syndrome | Mutations in JAG1/NOTCH2 → paucity of intrahepatic bile ducts | Characteristic facies (triangular face, broad forehead, pointed chin), posterior embryotoxon (eye), butterfly vertebrae, peripheral pulmonary stenosis [3] |
| Inspissated bile syndrome | Concentrated bile plugs ducts; often follows haemolytic disease (high bilirubin load) | History of severe haemolysis; resolves as bilirubin load decreases |
| Bile acid synthesis defects | Deficiency of enzymes for primary bile acid synthesis → toxic bile acid intermediates accumulate → cholestasis | Respond to oral cholic acid therapy |
| Progressive familial intrahepatic cholestasis (PFIC) types 1–3 | Defects in bile acid/phospholipid transporters (FIC1, BSEP, MDR3) → cholestasis | Low GGT in PFIC1/2 (important distinguishing feature from biliary atresia which has high GGT); high GGT in PFIC3 |
| Dubin-Johnson syndrome / Rotor syndrome | Defective canalicular excretion (DJS: MRP2 mutation) or defective hepatocyte storage (Rotor) of conjugated bilirubin | Both benign; isolated conjugated hyperbilirubinaemia with otherwise normal LFT. DJS: grossly black liver on biopsy. Rare in neonates. [13][16] |
An alternative way to organise the same information — useful for understanding "why":
| Mechanism | Examples | Bilirubin Type |
|---|---|---|
| ↑ Bilirubin production (haemolysis, extravasation, polycythaemia) | ABO/Rh incompatibility, G6PD, HS, PKD, thalassaemia, cephalhaematoma, polycythaemia (IDM), DIC | Unconjugated |
| ↓ Hepatic uptake | Drugs (rifampicin — rare in neonates), Gilbert syndrome, hypothyroidism | Unconjugated |
| ↓ Conjugation | Physiological (immature UDPGT), Crigler-Najjar I/II, Gilbert, hypothyroidism, breast milk jaundice | Unconjugated |
| ↑ Enterohepatic circulation | Breastfeeding jaundice (↓ feeding), breast milk jaundice (β-glucuronidase), pyloric stenosis, any cause of ileus/↓ gut motility | Unconjugated |
| ↓ Canalicular excretion | Dubin-Johnson syndrome, PFIC, drugs | Conjugated |
| Bile duct obstruction (extrahepatic) | Biliary atresia, choledochal cyst, inspissated bile | Conjugated |
| Intrahepatic cholestasis / hepatocyte damage | Neonatal hepatitis, metabolic (galactosaemia, tyrosinaemia, citrin deficiency, α₁-AT def), PNAC, Alagille, GALD | Conjugated |
| Mixed | Congenital infection (TORCH) — both haemolysis and hepatitis; sepsis | Both |
4. Distinguishing Key "Look-Alike" Differentials
This is the most classic and important paediatric exam differential [3][9][10].
| Feature | Biliary Atresia | Neonatal Hepatitis |
|---|---|---|
| Stool colour | Persistently acholic (pale/clay-coloured) | Intermittently pale but often pigmented |
| GGT | ↑↑↑ (very high) | Mildly elevated or normal |
| USG abdomen | Contracted or absent gallbladder; triangular cord sign [10] | Normal/enlarged gallbladder |
| EHIDA scan (cholescintigraphy) | No excretion into intestine (even after 5 days phenobarbitone pre-treatment) | Delayed but eventually some excretion seen [14] |
| Liver biopsy | Bile duct proliferation, bile plugs, portal fibrosis (features of extrahepatic biliary obstruction) | Giant cell transformation, lobular disarray, minimal bile duct proliferation |
| Operative cholangiogram | Gold standard — fails to outline normal biliary tree [10] | Normal biliary anatomy |
| Urgency | Surgical emergency — Kasai before 60 days | Medical management; most self-limiting |
GC 146 Take Home Message — Causes of Conjugated Hyperbilirubinaemia and Biliary Atresia
The GC lecture (GC 146) explicitly lists as high-yield take-home messages:
- Causes of conjugated hyperbilirubinaemia in the neonatal period
- Biliary atresia — its recognition, investigation, and the time-critical nature of Kasai portoenterostomy
These are very likely to appear on in-house summative exams. [9]
| Feature | Breastfeeding Jaundice | Breast Milk Jaundice |
|---|---|---|
| Timing | First 3–5 days | After Day 4–7, peaks at 2 weeks, may persist 12 weeks |
| Mechanism | Inadequate caloric intake → dehydration → ↑ enterohepatic circulation [3][11] | Breast milk substances (β-glucuronidase, lipase-generated FFAs, EGF) inhibit UDPGT or ↑ intestinal bilirubin absorption [3][11][15] |
| Baby's condition | May be dehydrated, losing weight | Well, thriving, gaining weight |
| Management | Improve feeding technique, increase frequency (8–12×/day), supplement if severe dehydration | Reassurance; continue breastfeeding [3] |
Physiological jaundice is a diagnosis of EXCLUSION [3]. The following features make it pathological:
| Red Flag | Implies |
|---|---|
| Onset < 24 hours | Haemolysis |
| Rate of rise > 85 µmol/L/day ( > 5 mg/dL/day) | Overwhelming bilirubin production (haemolysis) |
| TSB exceeds age-specific phototherapy threshold | Risk of BIND |
| Persists > 2 weeks (term) / > 3 weeks (preterm) | Need to fractionate bilirubin |
| Any conjugated bilirubin elevation | Hepatobiliary disease |
| Unwell baby, poor feeding, hepatomegaly, pale stools | Infection, cholestasis |
| Condition | HK Relevance |
|---|---|
| G6PD deficiency | ~4–6% of males; X-linked; all male neonates screened at birth via cord blood in HK. Triggers locally include mothballs (naphthalene — still used in some households), fava beans, and traditional Chinese medicines. [3][11] |
| α/β-thalassaemia trait | α-thal carrier rate 3–5% in Southern Chinese; β-thal carrier rate ~2%. Usually NOT a cause of significant NNJ (carrier state), but severe forms (Hb Bart's hydrops, β-thal major) cause haemolysis. |
| Biliary atresia | Higher incidence in East Asians. Hong Kong uses the stool colour card at the 1-month well-baby check to screen for acholic stools. |
| Congenital hypothyroidism | Incidence ~1:3,000 in HK; screened by cord blood TSH [8]. If missed → prolonged jaundice + developmental delay (cretinism). |
| Citrin deficiency (NICCD) | Relatively common IEM in East Asians (estimated carrier rate ~1:65 in Chinese). Presents with neonatal cholestasis, fatty liver, failure to thrive. |
| HBV vertical transmission | HK has high HBV endemicity. Perinatal HBV transmission from HBsAg-positive mothers can cause neonatal hepatitis → conjugated jaundice. Universal HBV vaccination + HBIG given at birth. |
| Timing | Unconjugated Causes | Conjugated Causes |
|---|---|---|
| < 24h | ABO/Rh/other blood group incompatibility, G6PD deficiency, hereditary spherocytosis, α-thal major, PKD, congenital infection (may also have conjugated component) | Congenital infection (mixed) |
| 24h – 2 weeks | Physiological jaundice, breastfeeding jaundice, breast milk jaundice, infection (UTI), haemolysis, cephalhaematoma, polycythaemia, Crigler-Najjar | Uncommon at this stage; consider congenital infection, GALD |
| > 2 weeks term / > 3 weeks preterm | Breast milk jaundice, hypothyroidism, infection, ongoing haemolysis, pyloric stenosis, Gilbert syndrome | Biliary atresia, choledochal cyst, neonatal hepatitis, metabolic/IEM (galactosaemia, tyrosinaemia, citrin deficiency, α₁-AT deficiency, CF), PNAC, Alagille, PFIC, inspissated bile, Dubin-Johnson/Rotor, bile acid synthesis defects |
High Yield Summary — Differential Diagnosis of Neonatal Jaundice
- First step: fractionate bilirubin → unconjugated vs conjugated. This dictates the entire differential.
- Second step: timing → early ( < 24h), normal (24h–2w), or prolonged ( > 2w term / > 3w preterm).
- Jaundice < 24 hours = haemolysis until proven otherwise (ABO > Rh > G6PD > membrane defects > congenital infection).
- Physiological jaundice is a diagnosis of EXCLUSION — must rule out pathological causes first.
- Breastfeeding jaundice ≠ breast milk jaundice: the former = inadequate intake (baby losing weight); the latter = breast milk substances inhibiting conjugation (baby thriving).
- Prolonged conjugated jaundice → MUST exclude biliary atresia — it is surgically treatable but time-critical (Kasai before 60 days). Acholic stools are the key clue.
- Biliary atresia vs neonatal hepatitis: persistent acholic stools + very high GGT + contracted GB on USG + no intestinal excretion on EHIDA → biliary atresia. Confirmed by operative cholangiogram (gold standard).
- HK-specific: G6PD screening at birth (cord blood), congenital hypothyroidism screening (cord TSH), stool colour card at 1-month check for biliary atresia, citrin deficiency is relatively common in Chinese.
- Conjugated bilirubin does NOT cause kernicterus — but signals serious hepatobiliary disease.
- UTI is an easily missed cause of neonatal jaundice — always check urine in any unexplained jaundice.
Active Recall — Differential Diagnosis of Neonatal Jaundice
References
[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 46–48, 264) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 311) [6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 666) [8] Senior notes: Block A - I am losing weight and sweating all the time: causes of severe weight loss; thyrotoxicosis; hypothyroidism.pdf (p. 41) [9] Lecture slides: GC 146. A jaundiced child.pdf (p. 48) [10] Senior notes: Maksim Surgery Notes.pdf (pp. 121, 333) [11] Senior notes: Maksim Paediatric Notes.pdf (p. 8) [12] Senior notes: Block A - Family history of anaemia: inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf (p. 3) [13] Senior notes: Ryan Ho GI.pdf (pp. 191–192, 292) [14] Senior notes: Ryan Ho Haemtology.pdf (p. 38) [15] Paediatrics in Review - Jaundice - Newborn to Age 2 Months.pdf (pp. 3, 7–8) [16] Senior notes: Maksim Medicine Notes.pdf (pp. 121, 150)
Diagnostic Criteria, Diagnostic Algorithm, and Investigation Modalities for Neonatal Jaundice
1. Defining Thresholds and Diagnostic Criteria
Unlike many medical conditions, neonatal jaundice does not have a single "diagnostic criterion" in the traditional sense. Instead, we work with age-specific thresholds and a set of criteria that distinguish physiological from pathological jaundice, and unconjugated from conjugated hyperbilirubinaemia.
Physiological jaundice is a diagnosis of exclusion — you make it only after ruling out pathological causes [3][4]. All of the following must be met:
| Criterion | Rationale |
|---|---|
| Onset after 24 hours of age | Jaundice < 24h = haemolysis until proven otherwise |
| Peaks Day 2–3 (Caucasians) or Day 4–5 (Asians) [4][6] | Expected timing of physiological bilirubin peak |
| TSB within age-specific normal range (typically < 200–220 µmol/L / 12 mg/dL in term) | Exceeding threshold → pathological |
| Rate of rise < 85 µmol/L/day ( < 5 mg/dL/day) | Rapid rise implies overwhelming production (haemolysis) |
| Resolves within 2 weeks (term) or 3 weeks (preterm) | Persistence → requires bilirubin fractionation |
| Unconjugated hyperbilirubinaemia only — conjugated fraction normal | Any conjugated elevation = hepatobiliary pathology |
| Normal hepatic enzymes (parenchymal and ductal) [4][6] | Elevated enzymes suggest hepatitis or obstruction |
| No evidence of haemolysis on peripheral blood smear [4][6] | Spherocytes, fragments, polychromasia absent |
| Baby is well, feeding well, growing appropriately | Unwell baby = investigate further |
Conjugated (direct) hyperbilirubinaemia is defined as: [3]
Direct bilirubin > 17.1 µmol/L (1 mg/dL) OR > 15% of TSB
This is NEVER physiological and always mandates urgent investigation to exclude surgically treatable causes (especially biliary atresia) [3][9].
GC 146 High Yield — Conjugated Hyperbilirubinaemia in Neonatal Period
The GC 146 lecture explicitly states as a take-home message: "Causes of conjugated hyperbilirubinemia in neonatal period" and "Biliary atresia". In the neonatal period, the priority with conjugated hyperbilirubinaemia is to RULE OUT obstructive jaundice amendable to surgical treatment — biliary atresia and choledochal cyst [9].
Any ONE of the following makes jaundice pathological and warrants investigation [3][4][15]:
- Onset < 24 hours
- Rate of rise > 85 µmol/L/day ( > 5 mg/dL/day)
- TSB exceeds age-specific phototherapy threshold (Bhutani nomogram / AAP 2022 guidelines)
- Prolonged: > 2 weeks (term) or > 3 weeks (preterm)
- Any conjugated bilirubin elevation
- Signs of bilirubin encephalopathy (lethargy, hypotonia, poor feeding, high-pitched cry)
- Unwell baby (fever, hepatomegaly, pale stools, dark urine)
All term or near-term newborns (≥ 35 weeks GA) are screened using an hour-specific total serum or transcutaneous bilirubin nomogram [15].
- The Bhutani nomogram plots TSB against postnatal age in hours and categorises risk:
- Low-risk zone ( < 40th percentile)
- Low-intermediate zone (40th–75th percentile)
- High-intermediate zone (75th–95th percentile)
- High-risk zone ( > 95th percentile) → requires close follow-up and likely intervention
The nomogram is not designed for infants with active haemolysis or those requiring intensive care — these babies need individualised management [15].
The AAP 2022 revised guidelines (updated from the 2004 version) now use a more granular risk-based approach incorporating neurotoxicity risk factors (gestational age, albumin level, haemolytic disease, clinical instability) to set phototherapy and exchange transfusion thresholds.
4. Investigation Modalities — Detailed Breakdown
| Investigation | Technique | Key Findings & Interpretation |
|---|---|---|
| Transcutaneous bilirubinometer (TcB) | Non-invasive optical device applied to forehead + sternum; measures skin bilirubin by spectral reflectance [3] | Screening tool — usually two readings (forehead + sternum) [3]. If elevated → confirm with serum TSB. Less reliable after phototherapy (blanches skin) or in very dark/very light skin. |
| Visual assessment (Kramer's rule) | Inspect under natural light, pressing skin ("blanching") | Cephalocaudal progression: face ≈ 85 µmol/L → mid-abdomen ≈ 256 µmol/L → soles ≈ 342 µmol/L [3]. Unreliable for precise levels — always confirm with TcB or TSB. |
| Stool colour card | Parents compare baby's stool to standardised colour card (used in HK at 1-month check) | Persistent acholic (pale/clay) stools = biliary obstruction until proven otherwise — urgent referral for biliary atresia workup [9][15] |
| Urine inspection | Dark/tea-coloured urine | Indicates conjugated hyperbilirubinaemia (water-soluble conjugated bilirubin excreted by kidneys) [10][16] |
| Test | What It Tells You | Key Findings |
|---|---|---|
| Total serum bilirubin (TSB) — direct + indirect [3] | The definitive bilirubin measurement; fractionate into conjugated (direct) and unconjugated (indirect) | Plot on Bhutani nomogram for risk zone. Direct bilirubin > 17.1 µmol/L or > 15% TSB = conjugated hyperbilirubinaemia [3]. Aim to intervene before TSB reaches risky levels ( < 340 µmol/L / 20 mg/dL in term; lower threshold in preterm) [3]. |
| CBC with peripheral blood smear (PBS) | Evaluate for anaemia, haemolysis, infection | Anaemia + reticulocytosis + polychromasia = haemolysis. Spherocytes (HS or ABO). RBC fragments (DIC/microangiopathic). Nucleated RBCs (severe haemolysis/stress). Leucocytosis (infection). Thrombocytopenia (DIC, congenital infection, sepsis, hypersplenism) [12][14][15] |
| Reticulocyte count | Active bone marrow response to RBC destruction | ↑ Reticulocytes = haemolysis or blood loss. Expected in immune haemolysis, G6PD crisis, HS. |
| Blood group (mother and baby) + Direct Coombs test (DAT) [3][15] | Identify immune haemolysis | Positive DAT = antibodies on baby's RBCs (ABO or Rh incompatibility). Mother group O + baby A/B = ABO incompatibility. Mother Rh-negative + baby Rh-positive = Rh disease. Note: DAT may be weakly positive or even negative in ABO incompatibility (unlike Rh). [12] |
| G6PD assay (cord blood or neonatal screen) | Identify G6PD deficiency | Low/absent G6PD activity = G6PD deficiency. All male neonates in HK are screened at birth. Caution: G6PD levels may be falsely normal during acute haemolysis (reticulocytes have higher G6PD activity) — repeat when stable if high clinical suspicion. [3] |
| Cord blood TFT (TSH screening) | Screen for congenital hypothyroidism | TSH > 7 mIU/L with fT4 < 12 pmol/L at 2 weeks = suspicious for congenital hypothyroidism → cause of prolonged unconjugated jaundice [3][8] |
High Yield — Haemolysis Markers
Markers of haemolysis in neonatal jaundice [3][12]:
- ↑ Unconjugated bilirubin
- ↑ LDH — a quick marker; "if LDH is high, think high turnover / haemolysis" [12]
- ↓ Haptoglobin — consumed binding free haemoglobin (may be unreliable in neonates as baseline is low)
- ↑ Reticulocyte count — bone marrow compensation
- ↑ Methaemalbumin — when haptoglobin is exhausted, free haem binds albumin [3]
- ↑ AST (released from RBCs during haemolysis — AST is less liver-specific than ALT) [15]
- PBS: polychromasia, spherocytes, fragments depending on cause
This is a separate and urgent investigation pathway triggered whenever conjugated bilirubin is elevated [9][15][17].
GC 157 (Paediatric Chemical Pathology) lists "First-line investigations of neonatal cholestasis" — this is high-yield exam content [17].
| Test | Purpose | Key Findings & Interpretation |
|---|---|---|
| LFT — full panel | Assess hepatocellular injury and ductal obstruction | ↑ Conjugated bilirubin (by definition). ↑ GGT — very important: markedly elevated GGT suggests biliary atresia, while normal/low GGT in cholestasis suggests PFIC type 1 or 2 [15]. ↑ ALP (note: neonatal ALP is physiologically higher due to bone isoenzyme — confirm hepatic origin by checking GGT [18][19]). ↑ ALT/AST = hepatocellular injury component. |
| Coagulation profile (PT/INR) | Assess hepatic synthetic function; detect vitamin K deficiency | Prolonged PT/INR may be due to: (1) cholestasis → ↓ bile salt secretion → ↓ fat-soluble vitamin K absorption → ↓ factors II, VII, IX, X (responsive to parenteral vitamin K), OR (2) hepatocellular failure (unresponsive to vitamin K) [15][16]. Distinguish by giving IV vitamin K and re-checking PT in 24h. |
| Albumin | Hepatic synthetic function | ↓ Albumin = impaired synthesis (subacute/chronic liver disease) |
| Blood glucose | Hepatic metabolic function | Hypoglycaemia in acute liver failure or certain IEMs (galactosaemia) |
| Ammonia (NH₃) | Hepatic detoxification function | ↑ NH₃ = liver failure or urea cycle defect |
| Fasting USG abdomen | First-line imaging for biliary anatomy | Biliary atresia: contracted or absent gallbladder, triangular cord sign (echogenic fibrous remnant at porta hepatis), hepatomegaly. Choledochal cyst: cystic dilatation of bile duct. Normal gallbladder does NOT exclude BA (may occasionally be seen) [3][10]. |
| Urine (dipstick + culture) | Rule out UTI — a common occult cause of jaundice in neonates | UTI can cause both unconjugated and conjugated jaundice; always perform in any neonate with unexplained jaundice |
| TORCH screen (serology + urine CMV PCR) | Congenital infection workup | CMV (urine PCR is gold standard in first 3 weeks), toxoplasma IgM, rubella IgM, HSV PCR |
| Newborn metabolic screen review | IEM detection | Review results of the dried blood spot newborn screening programme (includes amino acids, acylcarnitines, thyroid function) |
| Test | Technique | Key Findings & Interpretation |
|---|---|---|
| Hepatobiliary scintigraphy (EHIDA / HIDA scan) [14][15] | Pre-treatment with phenobarbitone 5 mg/kg PO × 5 days (to induce hepatic enzymes and ↑ biliary secretion) → inject ⁹⁹ᵐTc-mebrofenin IV → dynamic anterior abdominal imaging for 60 minutes, with delayed images at 4–24h [14] | Biliary atresia: no excretion of isotope into intestine even on delayed images (high sensitivity ~100%, but specificity only ~60–70% — hence it is a good "rule-out" test rather than confirmatory) [15]. Neonatal hepatitis: delayed but eventually some intestinal excretion seen. |
| Liver biopsy (percutaneous, typically at 4–6 weeks of age) | Histological assessment | Biliary atresia: bile duct proliferation, bile plugs in ductules, portal tract expansion/fibrosis (features of extrahepatic biliary obstruction) [3]. Neonatal hepatitis: giant cell transformation, lobular disarray, minimal duct proliferation. α₁-AT deficiency: PAS-positive, diastase-resistant globules in hepatocytes. Alagille: paucity of interlobular bile ducts. Should be performed at 4–6 weeks to avoid delays in surgical intervention if BA is suspected [15]. |
| Operative (intraoperative) cholangiogram | Gold standard for biliary atresia — performed at laparoscopy/laparotomy; contrast injected into gallbladder | Fails to outline normal biliary tree in BA (contrast does not pass into intrahepatic ducts or duodenum) → proceed directly to Kasai portoenterostomy [3][10]. |
| MRCP | MRI of biliary tree — non-invasive but requires GA in neonates | Can delineate biliary anatomy, detect choledochal cyst; T2-weighted MRI may show siderosis in GALD [15]. Less reliable in very small infants. |
| ERCP | Endoscopic assessment of biliary tree — technically very challenging in neonates | Reserved for therapeutic need (e.g., biliary irrigation, sphincterotomy for sludge/stones). Requires GA. [15] |
GC 146 + GC 157 — Biliary Atresia Investigation Pathway
From the GC slides, the investigation pathway for suspected biliary atresia is:
- LFT: ↑ conjugated bilirubin, ↑ GGT (obstructive pattern) [3]
- Fasting USG abdomen: contracted/absent gallbladder, triangular cord sign [10]
- EHIDA scan: no excretion into intestine (after 5-day phenobarbitone pre-treatment) [14]
- Liver biopsy: features of extrahepatic biliary obstruction [3]
- Operative cholangiogram: gold standard — fails to outline normal biliary tree [3][10]
| Test | Target Condition |
|---|---|
| Urine reducing substances (Clinitest, NOT dipstick) | Galactosaemia — positive for galactose (note: dipstick only detects glucose, NOT galactose) |
| Plasma amino acids | Tyrosinaemia (↑ tyrosine), citrullinaemia/citrin deficiency (↑ citrulline) |
| Urine organic acids | Organic acidaemias, tyrosinaemia (↑ succinylacetone) |
| Acylcarnitine profile (dried blood spot) | Fatty acid oxidation defects, organic acidaemias [20][21] |
| Serum α₁-antitrypsin level + phenotyping | α₁-AT deficiency (PiZZ phenotype) |
| Sweat chloride test | Cystic fibrosis (rare in Chinese but must consider) |
| Serum ferritin + lip biopsy (minor salivary gland iron stain) | Neonatal haemochromatosis / GALD |
| Plasma bile acids | Bile acid synthesis defects (elevated atypical bile acids) |
| Genetic testing (targeted or whole exome sequencing) | Alagille (JAG1/NOTCH2), PFIC (ATP8B1, ABCB11, ABCB4), citrin deficiency (SLC25A13), etc. |
| Consideration | Explanation |
|---|---|
| Normal neonatal GGT values may be 5–8× adult levels | Do not diagnose cholestasis on GGT alone — interpret in context of conjugated bilirubin and clinical picture [15] |
| ALP is physiologically elevated in neonates and children (due to bone isoenzyme from growth) | Confirm hepatic origin by checking GGT — if both ALP and GGT are elevated → ductal pathology [18][19] |
| Neonatal haematological normals differ from adults | Hb 14–22 g/dL, Hct 50–60%, MCV 95–115 fL at birth. Reticulocyte count normally 3–7% in first 3 days (higher than adults). Always use age-specific reference ranges. |
| G6PD assay timing | May be falsely normal during acute haemolysis (reticulocytes have higher G6PD) — repeat when stable |
| Liver biopsy timing | Typically performed at 4–6 weeks of age [15] to allow time for initial workup but avoid delaying surgery for BA |
| Consent | All investigations in neonates require parental/guardian consent. Explain clearly why blood tests, ultrasound, or liver biopsy are needed. For operative cholangiogram — this is performed under GA at laparoscopy, with consent for possible Kasai procedure at the same sitting. |
| Pattern | Key LFT Changes | Interpretation |
|---|---|---|
| Pre-hepatic (haemolysis) | ↑ Unconjugated bilirubin, normal ALT/AST (unless severe), normal ALP/GGT, normal albumin | RBC destruction → excess bilirubin production overwhelms conjugation capacity [13][16] |
| Hepatocellular (hepatitis) | ↑ Conjugated bilirubin, ↑↑↑ ALT/AST, mildly ↑ ALP/GGT, ↓ albumin (if subacute), ↑ PT/INR | Hepatocyte injury → leakage of intracellular enzymes + impaired synthetic and excretory function [13][19] |
| Obstructive / cholestatic | ↑ Conjugated bilirubin, mildly ↑ ALT/AST, ↑↑↑ ALP and GGT, normal albumin (initially) | Bile duct obstruction → back-pressure → ductal enzyme induction and leakage. This is the pattern of biliary atresia [3][13][19] |
Key exam point: In neonates, a falling ALT/AST can mean recovery, BUT if PT/INR is simultaneously worsening → suspect fulminant hepatic failure (massive hepatocyte necrosis with few viable cells left to release enzymes) [15].
The van den Bergh reaction is a colorimetric test using sulfanilic acid (diazo reagent) that reacts with bilirubin to form a purple azobilirubin [3]:
| Result | Mechanism | Interpretation |
|---|---|---|
| Direct positive — turns purple immediately | Conjugated (water-soluble) bilirubin reacts directly with reagent without added alcohol | Obstructive / cholestatic jaundice |
| Indirect positive — turns purple only after alcohol addition | Unconjugated (lipid-soluble) bilirubin requires alcohol to dissolve before it can react | Haemolytic / pre-hepatic jaundice |
| Biphasic — turns purple immediately AND intensifies with alcohol | Both conjugated and unconjugated fractions present | Hepatic jaundice (mixed) |
While largely replaced by automated fractionation, this is still tested in exams.
High Yield Summary — Diagnostic Approach to Neonatal Jaundice
- Step 1 — Screen: TcB (non-invasive) → if elevated, confirm with serum TSB → plot on Bhutani nomogram.
- Step 2 — Fractionate: Always determine conjugated vs unconjugated bilirubin. This is THE branch point.
- Step 3 — Unconjugated pathway: CBC, PBS, reticulocyte count, blood group + Coombs test, G6PD assay, LDH. Looking for haemolysis.
- Step 4 — Conjugated pathway (cholestasis): Full LFT (especially GGT), coagulation profile, albumin, glucose, USG abdomen, urine culture, TORCH screen, metabolic screen. Looking for biliary atresia, neonatal hepatitis, IEM.
- Step 5 — Biliary atresia workup: Fasting USG (contracted GB, triangular cord sign) → EHIDA scan (no intestinal excretion after phenobarbitone pre-treatment) → liver biopsy (bile duct proliferation, portal fibrosis) → operative cholangiogram (gold standard).
- Step 6 — Prolonged jaundice ( > 2 weeks term / > 3 weeks preterm): MUST fractionate bilirubin. If unconjugated → check TFT, urine culture, feeding adequacy. If conjugated → cholestasis pathway (as above).
- Physiological jaundice = diagnosis of exclusion. Unconjugated only, normal enzymes, no haemolysis, well baby, resolves by 2 weeks.
- Conjugated hyperbilirubinaemia is NEVER physiological → always warrants urgent investigation.
- In HK: cord blood G6PD screen (males), cord TSH screen, stool colour card at 1 month.
Active Recall — Diagnostic Criteria, Algorithm, and Investigations for Neonatal Jaundice
References
[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 46–49, 264) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 311, 313) [6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 666) [8] Senior notes: Block A - I am losing weight and sweating all the time: causes of severe weight loss; thyrotoxicosis; hypothyroidism.pdf (p. 41) [9] Lecture slides: GC 146. A jaundiced child.pdf (pp. 35, 48) [10] Senior notes: Maksim Surgery Notes.pdf (pp. 121, 333) [12] Senior notes: Block A - Family history of anaemia: inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf (pp. 3–4) [13] Senior notes: Ryan Ho GI.pdf (pp. 191, 193) [14] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p. 64) [15] Paediatrics in Review - Jaundice - Newborn to Age 2 Months.pdf (pp. 1, 3–4, 7–9) [16] Senior notes: Maksim Medicine Notes.pdf (pp. 119, 121) [17] Lecture slides: GC 157. Paediatric Chemical Pathology.pdf (p. 6) [18] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy).pdf (pp. 9–10) [19] Senior notes: Learning_Points_All_Lectures.txt (Section 1) [20] Senior notes: Ryan Ho Chemical Path.pdf (p. 56) [21] Lecture slides: Chemical Pathology Seminar_Inherited metabolic disease 2025.pdf (p. 13)
Management Algorithm and Treatment Modalities for Neonatal Jaundice
The management of neonatal jaundice is not a "one-size-fits-all" approach. It depends on:
- Is the jaundice unconjugated or conjugated? — Entirely different management pathways.
- What is the underlying cause? — Treat the cause when identifiable.
- How high is the bilirubin and how fast is it rising? — Determines urgency of intervention.
- What is the gestational age and postnatal age? — Thresholds are lower in preterm and younger neonates.
- Are there neurotoxicity risk factors? — These lower the threshold for treatment.
The overarching goals are [3][7][15]:
- Prevent bilirubin-induced neurological dysfunction (BIND) / kernicterus — the feared complication of unconjugated hyperbilirubinaemia
- Identify and treat the underlying cause (especially surgically treatable conjugated causes like biliary atresia)
- Support feeding and nutrition
- Communicate clearly with parents — family-centred care is paramount
3. Management of Unconjugated Hyperbilirubinaemia
| Measure | Rationale | Details |
|---|---|---|
| Optimise feeding | ↑ Enteral intake → ↑ gut motility → ↑ stool output → ↓ enterohepatic circulation → ↓ bilirubin reabsorption [7][15] | Breastfeed 8–12 times/day. If breastfeeding inadequate (excess weight loss > 7–10% birth weight), consider supplemental expressed breast milk or formula. Do NOT stop breastfeeding for breast milk jaundice — continue and reassure [3][6]. |
| Adequate hydration | Dehydration concentrates bilirubin and reduces gut transit | Assess hydration by urine output (at least 6 wet nappies/day by Day 4), weight trajectory, and clinical exam |
| Monitor bilirubin | Track trajectory — is it rising, stable, or falling? | Serial TcB or TSB plotted on nomogram. Frequency depends on risk zone (Q6–24h) |
| Parent education | Family-centred care — empower parents to recognise warning signs | Explain jaundice, its usual benign course, when to seek help (increasing yellow, poor feeding, lethargy, pale stools, dark urine). In HK, provide stool colour card at discharge. |
Never Stop Breastfeeding for Breast Milk Jaundice
Breast milk jaundice is benign, and mother should be advised to continue breastfeeding based on other beneficial effects of breastmilk [3][6]. The bilirubin will gradually decline over 3–12 weeks. Temporary interruption of breastfeeding for diagnostic purposes (to see if TSB drops) is rarely needed and generally discouraged because it undermines breastfeeding establishment.
3B. Phototherapy — The Primary Treatment
Phototherapy ("photo" = light, "therapy" = treatment) is the mainstay of treatment for unconjugated neonatal hyperbilirubinaemia. It is by far the most commonly used intervention.
Phototherapy works by three photochemical reactions that convert unconjugated bilirubin (lipophilic, neurotoxic) into water-soluble photoisomers that can be excreted without hepatic conjugation:
- Structural isomerisation (photo-oxidation): Bilirubin → lumirubin (most important pathway). Lumirubin is water-soluble → excreted rapidly in bile and urine without requiring conjugation. This is the dominant clearance pathway.
- Configurational (geometric) isomerisation: Native bilirubin (4Z,15Z) → photobilirubin (4Z,15E or 4E,15Z). These isomers are more polar → excreted in bile. Reversible — can revert to native form.
- Photo-oxidation: Small contribution — bilirubin broken down into colourless, water-soluble fragments.
Why does the light need to be blue-green (wavelength 460–490 nm)? Because this is the absorption spectrum of bilirubin — light at this wavelength is maximally absorbed by bilirubin molecules in the skin and subcutaneous tissue, driving the photochemical conversion.
| Type | Description | Indication |
|---|---|---|
| Conventional (standard) phototherapy | Single overhead light source (fluorescent, LED, or fibreoptic) | TSB at or above phototherapy threshold for age |
| Intensive phototherapy | Multiple light sources (overhead + underneath fibreoptic blanket) → maximises irradiance and body surface area exposed | TSB rapidly rising, approaching exchange transfusion threshold, or in high-risk zone |
| Aspect | Detail |
|---|---|
| Position | Baby undressed (maximise skin exposure) with only a nappy. Eye shields (opaque) to protect retinae from phototoxicity |
| Distance | Light source as close to baby as possible (for conventional units, typically 30–50 cm; LED can be closer) — irradiance is inversely proportional to distance |
| Feeding | Continue breastfeeding. Remove baby from phototherapy for feeds (intermittent phototherapy is acceptable for feeding) |
| Monitoring | TSB every 4–6 hours initially under phototherapy to assess response. Once falling, can space to every 12–24 hours. |
| Hydration | Phototherapy increases insensible water loss (evaporation from exposed skin) → may need to increase fluid intake by ~10–20%. Monitor urine output and weight. |
| When to stop | When TSB falls to a level at least 35–50 µmol/L (2–3 mg/dL) below the phototherapy threshold for that age. Check rebound TSB 12–24 hours after stopping — especially important in haemolytic disease where rebound can occur. |
The AAP 2022 revised clinical practice guideline (replacing the 2004 guideline) recommends phototherapy based on:
- TSB level plotted against postnatal age in hours on an age-specific nomogram
- Gestational age (lower thresholds for lower GA)
- Neurotoxicity risk factors — which lower the phototherapy threshold by approximately one risk category:
- GA 35–37+6 weeks (late preterm)
- Albumin < 3.0 g/dL
- Isoimmune haemolytic disease (positive DAT)
- G6PD deficiency
- Sepsis
- Clinical instability in the previous 24 hours
- Significant lethargy
| GA | Approximate Phototherapy Threshold at 48h | At 72h |
|---|---|---|
| ≥ 38 weeks, no risk factors | ~15 mg/dL (257 µmol/L) | ~18 mg/dL (308 µmol/L) |
| ≥ 38 weeks, with risk factors | ~13 mg/dL (222 µmol/L) | ~15 mg/dL (257 µmol/L) |
| 35–37+6 weeks, no risk factors | ~13 mg/dL (222 µmol/L) | ~15 mg/dL (257 µmol/L) |
| 35–37+6 weeks, with risk factors | ~11 mg/dL (188 µmol/L) | ~13 mg/dL (222 µmol/L) |
(These are approximate guides — always use the published nomogram charts in clinical practice)
| Situation | Reasoning |
|---|---|
| Conjugated hyperbilirubinaemia | Phototherapy is ineffective (conjugated bilirubin is already water-soluble — it does not need photoisomerisation). Worse, phototherapy can cause "bronze baby syndrome" — deposition of photodegradation products of conjugated bilirubin in skin → bronze-grey discolouration. Harmless but alarming and cosmetically distressing. |
| Congenital erythropoietic porphyria (CEP) or other porphyrias | Phototherapy can trigger severe phototoxic blistering skin reactions |
High Yield — Phototherapy is for UNCONJUGATED Hyperbilirubinaemia Only
Phototherapy does NOT work for conjugated hyperbilirubinaemia — conjugated bilirubin is already water-soluble so photo-isomerisation is irrelevant. Using phototherapy on a baby with conjugated jaundice can cause bronze baby syndrome and delays the workup for the real underlying cause (e.g., biliary atresia). Always fractionate bilirubin before starting phototherapy.
| Side Effect | Mechanism |
|---|---|
| Insensible water loss / dehydration | Increased evaporation from exposed skin under radiant heat |
| Temperature instability | Exposed baby loses heat; some units radiate warmth |
| Loose green stools | Photoisomers excreted in bile → osmotic diarrhoea |
| Skin rash (erythema) | Photosensitivity |
| Bronze baby syndrome | Only with conjugated hyperbilirubinaemia (see above) |
| Retinal damage (if eyes unshielded) | UV/blue light phototoxicity → hence mandatory eye shields |
| Interference with parent-infant bonding | Baby under lights, eyes covered → parents feel separated; encourage kangaroo care during breaks |
| Aspect | Detail |
|---|---|
| Indication | Isoimmune haemolytic disease (positive DAT due to ABO or Rh incompatibility) where TSB is rising despite intensive phototherapy and approaching the exchange transfusion threshold [7][15] |
| Mechanism | IVIG blocks Fc receptors on reticuloendothelial system macrophages (in spleen and liver) → reduces antibody-mediated destruction of antibody-coated neonatal RBCs → slows haemolysis → ↓ bilirubin production |
| Dose | 0.5–1 g/kg IV over 2 hours. Can be repeated once in 12 hours if needed. |
| Goal | Reduce the need for exchange transfusion |
| Side effects | Rare: allergic reactions, fluid overload, necrotising enterocolitis (NEC) risk in preterm (some concern from observational data) |
3D. Exchange Transfusion — The Rescue Treatment
Exchange transfusion is the definitive emergency treatment for severe unconjugated hyperbilirubinaemia when phototherapy and IVIG fail, or when bilirubin levels are dangerously high and/or there are signs of acute bilirubin encephalopathy (ABE) [3][7][15].
A double-volume exchange transfusion (≈ 160–170 mL/kg for a term neonate, since blood volume ≈ 80–85 mL/kg) removes approximately:
- ~85% of circulating antibody-coated RBCs (in immune haemolysis)
- ~50% of intravascular bilirubin (bilirubin re-equilibrates from extravascular compartment afterwards)
- Circulating maternal antibodies
Fresh donor blood (cross-matched against mother's serum, usually group O Rh-negative or compatible) replaces the removed blood.
| Indication | Detail |
|---|---|
| TSB at or above the exchange transfusion threshold on the AAP 2022 nomogram | Thresholds are approximately 3–5 mg/dL above the phototherapy threshold and vary by GA and risk factors |
| TSB not responding to intensive phototherapy (continues rising rapidly) | Rate of rise > 8.5 µmol/L/h (0.5 mg/dL/h) despite intensive phototherapy |
| Signs of acute bilirubin encephalopathy (ABE) | Hypertonia, arching (opisthotonos/retrocollis), high-pitched cry, seizures — proceed immediately regardless of TSB level |
| Severe anaemia with cardiac compromise (haemolytic disease) | Hydrops fetalis, severe Rh disease |
| Postnatal Age | No Risk Factors | With Risk Factors |
|---|---|---|
| 24 hours | ~19 mg/dL (325 µmol/L) | ~17 mg/dL (291 µmol/L) |
| 48 hours | ~22 mg/dL (376 µmol/L) | ~19 mg/dL (325 µmol/L) |
| 72 hours | ~24 mg/dL (410 µmol/L) | ~21 mg/dL (359 µmol/L) |
(Lower thresholds for preterm infants — consult local nomograms)
Key teaching point: Aim to intervene before TSB reaches the risky level ( < 340 µmol/L / < 20 mg/dL in term) with a lower threshold in preterm infants [3].
- Performed in NICU with continuous cardiorespiratory monitoring
- Access: umbilical venous catheter (UVC) — tip positioned in IVC/right atrium
- Aliquots of 5–20 mL are withdrawn and replaced alternately with fresh donor blood
- Duration: ~1–2 hours
- Blood: Usually group O Rh-negative, irradiated, CMV-negative, fresh ( < 7 days old)
Why Irradiated Blood for Exchange Transfusion?
Exchange transfusion involves introducing a large volume of donor blood into an immunologically immature neonate. Non-irradiated blood contains viable donor lymphocytes that can engraft in the neonate's bone marrow → transfusion-associated graft-versus-host disease (TA-GVHD), which is almost universally fatal. Irradiation (25 Gy) destroys donor lymphocytes while preserving RBC function [22].
| Complication | Mechanism |
|---|---|
| Electrolyte disturbances (hypocalcaemia, hyperkalaemia, hypomagnesaemia) | Citrate anticoagulant in donor blood chelates calcium; stored blood leaks potassium |
| Cardiac arrhythmia / arrest | From electrolyte shifts (especially hypocalcaemia → ↓ ionised Ca²⁺ → QT prolongation) |
| Thrombocytopenia / coagulopathy | Dilution of platelets and clotting factors |
| Infection / sepsis | Invasive procedure; contamination risk |
| Air embolism | Via UVC |
| NEC | Gut ischaemia from haemodynamic shifts |
| Hypothermia | Large volume of cold blood infused |
| Rebound hyperbilirubinaemia | Bilirubin re-equilibrates from tissues after exchange → always continue phototherapy post-exchange and monitor TSB Q4–6h |
| Mortality | ~0.3–0.5% in modern NICUs — hence exchange transfusion is reserved for when benefits clearly outweigh risks |
| Agent | Mechanism | Use in Neonatal Jaundice |
|---|---|---|
| Phenobarbitone | Induces hepatic UGT1A1 (UDPGT) → ↑ conjugation; also ↑ ligandin → ↑ hepatic bilirubin uptake; ↑ bile flow | Not routinely used for treatment of NNJ (too slow onset — takes 3–5 days). Main role is pre-treatment before EHIDA scan to differentiate biliary atresia from neonatal hepatitis [14]. Historical use in Crigler-Najjar type II (responsive). |
| Tin-mesoporphyrin (Stannsoporfin) | Competitive inhibitor of haem oxygenase → ↓ bilirubin production at source | Investigational — FDA approved in some contexts. Not yet widely used in routine clinical practice. Potential to reduce need for phototherapy. |
| Albumin infusion | ↑ Bilirubin-binding capacity in blood → ↓ free bilirubin → ↓ neurotoxicity risk | Sometimes given before exchange transfusion (1 g/kg) in hypoalbuminaemic neonates to "mop up" free bilirubin. Not a standalone treatment. |
| Clofibrate | ↑ Conjugation (induces UGT) | Used in some centres as adjunct to phototherapy; not standard of care |
| Cause | Specific Treatment |
|---|---|
| ABO / Rh incompatibility | Phototherapy ± IVIG ± exchange transfusion as above |
| G6PD deficiency | Avoid oxidant triggers (mothballs, fava beans, sulfonamides, certain TCMs); supportive (transfusion if severe anaemia); folic acid supplementation [22b] |
| Infection / sepsis / UTI | Appropriate antimicrobials (e.g., ampicillin + gentamicin for empirical neonatal sepsis; targeted therapy after culture results) |
| Hypothyroidism | Levothyroxine replacement — early treatment preserves brain development |
| Crigler-Najjar type I | Long-term phototherapy (10–12h/day), liver transplantation (definitive cure) |
| Crigler-Najjar type II | Phenobarbitone (responsive — ↑ residual UGT activity) |
| Hereditary spherocytosis | Folic acid; transfusion if severe; splenectomy deferred until > 6 years [14b] |
| Polycythaemia | Partial exchange transfusion with normal saline (to reduce Hct) if symptomatic |
| Breastfeeding jaundice | Improve feeding technique and frequency; lactation support; supplement if severe dehydration |
4. Management of Conjugated Hyperbilirubinaemia (Neonatal Cholestasis)
This is an entirely different management pathway. Phototherapy and exchange transfusion have NO role here — conjugated bilirubin is already water-soluble and does not cause kernicterus. The focus is on:
- Identify and treat the underlying cause
- Nutritional support (universal for all cholestatic infants)
- Medical therapy where applicable
- Surgical intervention for obstructive causes
- Liver transplantation as definitive treatment when needed
| Component | Rationale | Details |
|---|---|---|
| MCT-based formula | In cholestasis, bile salt secretion into gut is ↓ → impaired emulsification and absorption of long-chain triglycerides (LCTs). Medium-chain triglycerides (MCTs) are absorbed directly into portal circulation without requiring bile salts for micelle formation. | Pregestimil, Pepti-Junior, or similar MCT-enriched formula |
| Fat-soluble vitamin supplementation (A, D, E, K) | ↓ Bile salts → ↓ fat absorption → ↓ absorption of fat-soluble vitamins → deficiency states | Vitamin K (1 mg IM or IV — prevents coagulopathy/bleeding); Vitamin D (oral cholecalciferol — prevents rickets); Vitamin A (oral); Vitamin E (oral α-tocopherol — prevents neuromuscular dysfunction). Monitor serum vitamin levels routinely [3][15][23] |
| Caloric supplementation | Cholestatic infants have high metabolic demands and poor absorption | Aim for 120–150% of normal caloric requirement for age |
| Protein | Adequate protein for growth | Standard protein intake unless hepatic encephalopathy (extremely rare in neonates — do not restrict protein unless absolutely necessary) |
Ursodeoxycholic Acid — Indication and Contraindication
Ursodeoxycholic acid (UDCA) is commonly used for intrahepatic cholestasis (e.g., Alagille syndrome, PFIC, neonatal hepatitis). It works by displacing toxic hydrophobic bile acids from the bile acid pool, promoting choleresis (bile flow), and has cytoprotective effects on hepatocytes. Dose: 10–20 mg/kg/day divided BD–TDS.
However, UDCA is contraindicated in extrahepatic biliary obstruction (e.g., biliary atresia before Kasai) — because stimulating bile flow against a complete obstruction worsens hepatocyte damage [15]. After a successful Kasai procedure with restored bile flow, UDCA is then started as part of post-operative medical therapy [23].
4B. Management of Biliary Atresia — The Surgical Priority
Biliary atresia is the most important surgical cause of neonatal cholestasis and the most common indication for paediatric liver transplantation [3][9].
| Aspect | Detail |
|---|---|
| Principle | A Roux-en-Y loop of jejunum is anastomosed to the cut surface of the porta hepatis (where the obliterated ducts are transected) → bile drains from microscopic patent ductules at the liver surface directly into the jejunal conduit → bypasses the fibrotic extrahepatic ducts [3][10] |
| Timing | Ideally before 60 days of life [10][23]. 60% achieve bile drainage (clear jaundice) if done before 12 weeks [3]; success rate drops significantly after 12 weeks. If diagnosed later than 6 weeks, some centres abandon Kasai and proceed directly to liver transplant listing [23]. |
| Post-operative medical therapy | Ursodeoxycholic acid (now safe — bile flow has been restored); Prophylactic antibiotics (e.g., co-trimoxazole or ciprofloxacin) to prevent ascending cholangitis via the jejunal conduit (which lacks a sphincter of Oddi); continued nutritional support and fat-soluble vitamins [10][23] |
| Outcomes | 70–80% early biliary drainage rate; 70–80% 5-year native liver survival (but the majority still develop progressive cirrhosis and portal hypertension) [10]. ~50% will eventually require liver transplantation. |
| Pre-operative preparation | Correct coagulopathy (vitamin K, FFP if needed); nutritional optimisation [10] |
| Aspect | Detail |
|---|---|
| Indication | Failed Kasai procedure (persistent jaundice post-Kasai); progressive liver failure; growth retardation / failure to thrive despite nutritional support; recurrent cholangitis; portal hypertension with complications (variceal bleeding, intractable ascites) [3][23] |
| Types | Whole liver (from deceased donor), split-liver (one donor organ shared between a child and an adult), living-donor (left lateral segment from a parent — preferred in HK due to organ scarcity) |
| Outcome | ~90% 5–10 year survival — comparable to transplantation for non-BA indications [3] |
| Post-transplant | Lifelong immunosuppression (tacrolimus-based regimen in most paediatric centres); monitoring for rejection, infection, PTLD (post-transplant lymphoproliferative disorder), renal toxicity |
| Cause | Treatment |
|---|---|
| Choledochal cyst | Complete surgical excision of the cyst + cholecystectomy + Roux-en-Y hepaticojejunostomy [10][23]. Do NOT simply drain — risk of cholangiocarcinoma with residual cyst lining. |
| Neonatal hepatitis (idiopathic) | Supportive: nutritional support, fat-soluble vitamins. Most self-limiting. Monitor for progression. |
| Galactosaemia | Immediate dietary elimination of galactose (stop all lactose-containing feeds → switch to soy-based formula) [23]. Delays worsen liver and brain damage. |
| Tyrosinaemia type 1 | Nitisinone (NTBC) — inhibits 4-hydroxyphenylpyruvate dioxygenase → prevents accumulation of toxic fumarylacetoacetate + dietary restriction of tyrosine and phenylalanine → liver transplant if refractory |
| α₁-antitrypsin deficiency | No specific enzyme replacement for liver disease. Supportive. Liver transplant for decompensated cirrhosis. |
| PNAC | Reduce IV lipid dose; advance enteral feeds as tolerated; consider fish-oil based lipid emulsion (SMOFlipid/Omegaven) which is less hepatotoxic than soybean-based emulsions [15] |
| Alagille syndrome | UDCA for cholestasis; nutritional support; partial external biliary diversion (PEBD) for intractable pruritus; liver transplant if decompensated |
| PFIC types 1–3 | UDCA; biliary diversion surgery (PEBD or ileal exclusion); BSEP stabiliser (investigational for type 2); liver transplant |
| Bile acid synthesis defects | Oral cholic acid — replaces missing primary bile acids, suppresses production of toxic intermediates |
| GALD (neonatal haemochromatosis) | Exchange transfusion + high-dose IVIG (removes circulating maternal alloantibodies + blocks complement-mediated hepatocyte injury); liver transplant if acute liver failure |
| Level | Treatment | Indication |
|---|---|---|
| Level 0 | Optimise feeding + monitoring | TSB below phototherapy threshold, baby well |
| Level 1 | Phototherapy (conventional) | TSB at or above phototherapy threshold |
| Level 2 | Intensive phototherapy (multiple light sources) | TSB rising rapidly, approaching exchange threshold, or not responding to conventional phototherapy |
| Level 3 | IVIG (if isoimmune haemolysis) + intensive phototherapy | TSB rising despite intensive phototherapy in immune haemolytic disease |
| Level 4 | Exchange transfusion | TSB at or above exchange threshold, or signs of ABE, or failure of all above |
| Group | Follow-Up Plan |
|---|---|
| Uncomplicated physiological jaundice | TcB/TSB check 24–48h post-discharge if discharged early ( < 72h of age); community midwife/nurse assessment; stool colour card education |
| Post-phototherapy | Rebound TSB 12–24h after stopping phototherapy (especially if haemolytic cause); clinic review in 1–2 weeks |
| Post-exchange transfusion | Close NICU follow-up; developmental surveillance (risk of hearing loss even if kernicterus averted); audiology referral |
| Biliary atresia (post-Kasai) | Lifelong follow-up — serial LFT, growth monitoring, liver USS, endoscopy for varices if portal hypertension develops; pre-transplant workup if failing |
| G6PD deficiency | Parental education on avoidance of oxidant triggers (mothballs, fava beans, sulphonamides, aspirin in high doses, certain TCMs); carry G6PD alert card; genetic counselling (X-linked) |
| Congenital hypothyroidism | Levothyroxine with regular TFT monitoring; developmental assessment |
High Yield Summary — Management of Neonatal Jaundice
- Unconjugated NNJ: Optimise feeding → Phototherapy (blue-green light, 460–490 nm, converts UCB to lumirubin) → IVIG (for isoimmune haemolysis) → Exchange transfusion (double-volume, last resort).
- Phototherapy thresholds are based on age-in-hours, gestational age, and neurotoxicity risk factors (AAP 2022 nomogram).
- Phototherapy is contraindicated in conjugated hyperbilirubinaemia — causes bronze baby syndrome and delays real diagnosis.
- Exchange transfusion removes ~85% of antibody-coated RBCs and ~50% of intravascular bilirubin. Use irradiated, CMV-negative, fresh blood. Complications: electrolyte shifts (hypocalcaemia!), infection, NEC, mortality ~0.3–0.5%.
- Conjugated NNJ: NO phototherapy. Nutritional support (MCT formula + fat-soluble vitamins A, D, E, K) for ALL. UDCA for intrahepatic cholestasis (contraindicated in extrahepatic obstruction until bile flow restored).
- Biliary atresia: Kasai portoenterostomy ideally before 60 days → post-op UDCA + prophylactic antibiotics → liver transplant if Kasai fails. BA is the most common indication for paediatric LT.
- Galactosaemia: Immediate dietary galactose elimination (soy formula).
- G6PD deficiency: Avoidance of triggers + supportive treatment.
- Always treat the underlying cause alongside managing the bilirubin level.
- Family-centred care: Explain treatment, educate on stool colour card, support breastfeeding, genetic counselling where appropriate.
Active Recall — Management of Neonatal Jaundice
References
[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 46–49, 264) [6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 668) [7] Unconjugated hyperbilirubinemia in newborns ≥35 weeks of gestation: Etiology and pathogenesis - UpToDate.pdf (p. 1) [9] Lecture slides: GC 146. A jaundiced child.pdf (pp. 35, 48) [10] Senior notes: Maksim Surgery Notes.pdf (pp. 121, 333) [14] Senior notes: Ryan Ho Diagnostic Radiology.pdf (pp. 64, 82) [14b] Senior notes: Ryan Ho Haemtology.pdf (p. 39) [15] Paediatrics in Review - Jaundice - Newborn to Age 2 Months.pdf (pp. 9–10) [22] Senior notes: Block A - Fever after a blood transfusion: transfusion and related problems.pdf (p. 22) [22b] Senior notes: Block A - Family history of anaemia: inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf (p. 21) [23] Senior notes: Maksim Paediatric Notes.pdf (pp. 85–86)
Complications of Neonatal Jaundice
The complications of neonatal jaundice fall into two broad categories: those arising from unconjugated hyperbilirubinaemia (bilirubin neurotoxicity) and those arising from conjugated hyperbilirubinaemia / neonatal cholestasis (progressive hepatobiliary damage and its sequelae). There are also complications of the treatments themselves. We will cover each systematically.
1. Complications of Unconjugated Hyperbilirubinaemia
The central feared complication is bilirubin-induced neurological dysfunction (BIND). To understand it, you need to understand the concept of "free" (unbound) bilirubin.
Why does unconjugated bilirubin damage the brain, but conjugated bilirubin does not?
- Unconjugated bilirubin (UCB) is lipophilic (fat-soluble). It normally circulates tightly bound to albumin, which is too large to cross the blood-brain barrier (BBB). As long as UCB remains albumin-bound, it cannot enter the brain.
- When the albumin-binding capacity is overwhelmed — either because the UCB level is extremely high, or because albumin is low, or because competing substances displace UCB from albumin — free (unbound) UCB enters the circulation.
- Free UCB, being lipophilic, readily crosses the BBB. It is directly toxic to neurons via:
- Mitochondrial toxicity (uncouples oxidative phosphorylation → energy failure)
- Excitotoxicity (↑ glutamate release)
- Oxidative stress (generates reactive oxygen species)
- Apoptosis of neurons
- The brain regions with the highest metabolic rate and the least myelination are most vulnerable: basal ganglia (globus pallidus, subthalamic nucleus), brainstem auditory nuclei (cochlear nuclei, inferior colliculus), hippocampus, and oculomotor nuclei.
- Conjugated bilirubin, by contrast, is hydrophilic (water-soluble). It does not cross the BBB and therefore does NOT cause kernicterus — instead, elevated conjugated bilirubin reflects underlying hepatobiliary disease [3][4].
Severe neonatal hyperbilirubinemia is defined as TSB > 428 µmol/L (25 mg/dL) — this level carries a significantly ↑ risk of BIND [4].
ABE is the acute clinical manifestation of bilirubin neurotoxicity. It is potentially reversible if recognised and treated urgently (with exchange transfusion) [3][4].
Clinical features progress through three phases:
| Phase | Timing | Features | Pathophysiology |
|---|---|---|---|
| Early | First 1–2 days | Lethargy, hypotonia, poor feeding, poor suck | Initial neuronal depression from bilirubin mitochondrial toxicity |
| Intermediate | Next 1–2 days | Irritability, high-pitched cry, hypertonia (alternating with hypotonia) | Progressive neuronal injury, especially basal ganglia irritability |
| Advanced | Beyond | Opisthotonos (severely arched back), retrocollis (arched neck), fever, apnoea, seizures → may progress to coma and death | Severe, widespread neuronal necrosis; brainstem compromise |
High Yield — ABE Warning Signs
The earliest signs of ABE are often subtle and non-specific — lethargy, poor feeding, hypotonia. These overlap with many other neonatal conditions (sepsis, metabolic disease). A high index of suspicion is required in any jaundiced neonate. If a jaundiced baby becomes "too sleepy" or "not feeding well" — check the TSB urgently.
The word "kernicterus" literally means "kern" (nucleus, German) + "icterus" (jaundice) — referring to the yellow staining of the basal ganglia and brainstem nuclei seen at autopsy.
Kernicterus is the chronic, irreversible form of BIND. If ABE is not treated in time, permanent neurological damage ensues [3][4].
The classic kernicterus tetrad:
| Feature | Brain Region Affected | Explanation |
|---|---|---|
| Dystonic / choreoathetoid cerebral palsy | Globus pallidus, subthalamic nucleus (basal ganglia) | Bilirubin selectively destroys the extrapyramidal motor system → involuntary writhing movements (athetosis), abnormal posturing (dystonia). NOT spastic CP — this is specifically extrapyramidal. |
| Sensorineural hearing loss (SNHL) | Cochlear nuclei, inferior colliculus (brainstem auditory pathway) | Auditory nuclei in the brainstem are highly vulnerable to bilirubin toxicity. SNHL can range from mild (auditory neuropathy spectrum disorder) to profound deafness. May occur even without other features of kernicterus — this is why all jaundiced neonates at risk should have auditory brainstem response (ABR) testing. |
| Upward gaze palsy | Vertical gaze centres in the midbrain (rostral interstitial nucleus of MLF) | Bilirubin damages the midbrain nuclei controlling vertical eye movements → eyes are "sunset" (unable to look upward) |
| Dental enamel dysplasia / greenish-brown teeth discolouration | Developing enamel-forming cells (ameloblasts) | Bilirubin is deposited in developing dental structures during amelogenesis |
Additional features may include: intellectual disability (variable severity, may be mild or severe), seizure disorder, and general developmental delay [3][4].
Key exam point: Kernicterus causes extrapyramidal (dystonic/choreoathetoid) cerebral palsy, NOT pyramidal (spastic) CP. This is because bilirubin targets the basal ganglia, not the corticospinal tracts.
| Risk Factor | Mechanism |
|---|---|
| Prematurity | Immature BBB (more permeable), lower albumin levels, lower albumin-binding affinity, developing brain is more susceptible |
| Hypoalbuminaemia | ↓ Binding capacity → ↑ free UCB at any given TSB level |
| Acidosis | H⁺ ions compete for bilirubin-binding sites on albumin → ↓ binding affinity → ↑ free UCB |
| Sepsis / infection | Opens BBB; causes acidosis and hypoalbuminaemia; ↑ bilirubin production from haemolysis |
| Drugs displacing bilirubin from albumin | Ceftriaxone, sulfonamides, ibuprofen — compete for the same binding site on albumin → ↑ free UCB |
| Haemolytic disease | Rapid ↑ in UCB can overwhelm binding capacity; also produces free fatty acids that displace bilirubin |
| Asphyxia / hypoxia | Disrupts BBB integrity; causes acidosis |
| Hypothermia | ↓ Albumin binding affinity |
| Hypoglycaemia | Impairs neuronal energy reserves → neurons more susceptible to bilirubin toxicity |
Even when kernicterus is prevented, there is emerging evidence that moderate-to-severe neonatal hyperbilirubinaemia may be associated with subtle neurodevelopmental effects including:
- Auditory processing difficulties (auditory neuropathy spectrum disorder — ANSD)
- Mild cognitive deficits
- Behavioural problems
This is why all neonates with significant jaundice (especially those requiring phototherapy or exchange transfusion) should be referred for audiology follow-up (ABR testing) and developmental surveillance [7].
2. Complications of Conjugated Hyperbilirubinaemia / Neonatal Cholestasis
Conjugated bilirubin itself is NOT directly neurotoxic. However, the diseases that cause conjugated hyperbilirubinaemia lead to a cascade of serious complications related to cholestasis and progressive liver disease [3][9][10][23].
Why does cholestasis cause fat-soluble vitamin deficiency?
- Bile salts are required for emulsification and absorption of dietary fats in the small intestine.
- In cholestasis, bile salt secretion into the gut is reduced → fat malabsorption → fat-soluble vitamins (A, D, E, K) are not absorbed.
- This leads to specific deficiency syndromes:
| Vitamin | Deficiency Manifestation | Mechanism | Clinical Relevance in Neonates |
|---|---|---|---|
| Vitamin K | Coagulopathy / bleeding (haemorrhagic disease of the newborn, easy bruising, GI bleeding, intracranial haemorrhage) | ↓ Vitamin K → ↓ carboxylation of factors II, VII, IX, X → ↑ PT/INR | Often the presenting feature; can be life-threatening. Prolonged PT/INR in a cholestatic neonate should be treated with parenteral (IM or IV) vitamin K — oral vitamin K is ineffective in cholestasis due to malabsorption. |
| Vitamin D | Rickets, osteopenia | ↓ Vitamin D → ↓ calcium absorption → ↓ bone mineralisation | May present with pathological fractures, widened wrists/ankles, frontal bossing if chronic |
| Vitamin E | Haemolytic anaemia, neuromuscular dysfunction (peripheral neuropathy, cerebellar ataxia, retinopathy) | Vitamin E is an antioxidant protecting cell membranes; deficiency → oxidative damage to RBCs and neurons | Often subclinical initially; neuromuscular complications develop over months–years if untreated |
| Vitamin A | Night blindness, xerophthalmia, keratomalacia | ↓ Vitamin A → ↓ rhodopsin in retinal rods; ↓ epithelial integrity | Rarely clinically apparent in neonates (detected by monitoring serum vitamin A levels) |
- Fat malabsorption → caloric deficit (fat is the most calorie-dense macronutrient)
- Steatorrhoea — fatty, foul-smelling, bulky stools
- ↓ Absorption of essential fatty acids (linoleic, linolenic acid) → can impair brain development
- Chronic liver disease itself increases metabolic demand
- Result: poor weight gain, failure to thrive, growth retardation — a common indication for liver transplantation [3]
- In biliary atresia, even after a successful Kasai procedure, the intrahepatic disease typically continues to progress → progressive fibrosis → biliary cirrhosis [3][10].
- Majority of biliary atresia patients still develop cirrhosis and portal hypertension even with initial bile clearance after Kasai [10].
- Death < 2 years if biliary atresia is untreated [3].
As cirrhosis develops, portal pressure rises (resistance to portal blood flow through the fibrotic liver). This leads to:
| Complication | Mechanism | Clinical Features |
|---|---|---|
| Splenomegaly and hypersplenism | Portal hypertension → congestion of spleen → splenic enlargement → sequestration of blood cells | Palpable spleen; thrombocytopenia, leucopenia, anaemia |
| Oesophageal and gastric varices | Portal blood diverts through collateral veins (including submucosal oesophageal veins) → dilated, fragile varices | Risk of variceal haemorrhage — haematemesis, melaena; can be life-threatening |
| Ascites | Portal hypertension + hypoalbuminaemia (↓ hepatic synthetic function) → ↑ hydrostatic pressure + ↓ oncotic pressure → transudation of fluid into peritoneal cavity | Abdominal distension, fluid thrill, shifting dullness |
| Hepatopulmonary syndrome | Intrapulmonary vascular dilatation → V/Q mismatch | Dyspnoea, cyanosis, clubbing (rare in neonates; more common in older children with chronic liver disease) |
After Kasai portoenterostomy, the Roux-en-Y jejunal conduit lacks a sphincter of Oddi → intestinal bacteria can ascend into the biliary system → recurrent ascending cholangitis [10][23].
- Presents with: fever, worsening jaundice, pale stools, acholic urine
- Can accelerate liver damage and cirrhosis
- Managed with IV antibiotics (e.g., ampicillin + gentamicin ± metronidazole) and prophylactic oral antibiotics (e.g., co-trimoxazole) are given long-term post-Kasai to reduce episodes [10]
- Chronic cholestasis and cirrhosis from any cause carry an increased risk of HCC, though this is more relevant in older children/adolescents with long-standing liver disease.
3. Complications of Treatment
| Complication | Mechanism |
|---|---|
| Insensible water loss / dehydration | ↑ Evaporation from exposed skin under radiant heat |
| Temperature instability | Naked baby under lights → heat gain or loss depending on environment |
| Loose green stools ("phototherapy diarrhoea") | Photoisomers excreted in bile → osmotic effect in gut |
| Erythematous skin rash | Photosensitivity reaction |
| Bronze baby syndrome | Only occurs with conjugated hyperbilirubinaemia — photodegradation products of conjugated bilirubin deposit in skin → grey-bronze discolouration. Cosmetically alarming but not harmful. Clears after phototherapy is stopped. |
| Retinal damage | UV/blue light phototoxicity → mandatory eye shields during phototherapy |
| Disruption of parent-infant bonding | Baby under lights with eyes covered → parents may feel distanced; encourage skin-to-skin during feed breaks |
| Separation from mother → breastfeeding disruption | May undermine breastfeeding establishment if not proactively supported |
Bronze Baby Syndrome — A Complication of Incorrect Indication
Bronze baby syndrome occurs when phototherapy is used on a baby with conjugated (not unconjugated) hyperbilirubinaemia. This is why bilirubin must ALWAYS be fractionated before starting phototherapy. The bronze discolouration is benign, but the real danger is that using phototherapy on a cholestatic baby delays the crucial workup for biliary atresia or other surgical causes.
| Complication | Mechanism | Prevention/Management |
|---|---|---|
| Hypocalcaemia | Citrate anticoagulant in stored donor blood chelates ionised calcium → ↓ iCa²⁺ → QT prolongation → risk of arrhythmia/cardiac arrest | Monitor iCa²⁺; give slow IV calcium gluconate 10% (0.5–1 mL/kg) after every 100 mL of blood exchanged |
| Hyperkalaemia | Stored blood leaks potassium from RBCs over time | Use fresh blood ( < 7 days old); monitor K⁺ |
| Thrombocytopenia / coagulopathy | Dilution of platelets and clotting factors during exchange | Check post-exchange CBC and coagulation; transfuse platelets/FFP if needed |
| Infection / sepsis | Invasive procedure (UVC); donor blood contamination | Strict asepsis; prophylactic antibiotics at some centres |
| Air embolism | Via umbilical venous catheter | Careful technique; Luer-lock connections |
| NEC (necrotising enterocolitis) | Gut ischaemia from haemodynamic shifts during exchange; especially in preterm infants | Withhold feeds during and briefly after exchange |
| Rebound hyperbilirubinaemia | Bilirubin re-equilibrates from extravascular compartment into blood after exchange | Continue phototherapy post-exchange; monitor TSB Q4–6h |
| Hypothermia | Large volume of cold blood infused | Use blood warmer |
| Graft-versus-host disease (TA-GVHD) | Viable donor lymphocytes engraft in immunologically immature neonate → attack host tissues | Use irradiated blood products |
| Mortality | All of the above | ~0.3–0.5% in modern NICUs |
| Complication | Detail |
|---|---|
| Allergic / anaphylactoid reaction | Rare; present with rash, hypotension |
| Fluid overload | Large-volume protein infusion in a small neonate |
| Possible NEC association | Some observational data suggest ↑ NEC risk in preterm infants receiving IVIG; not definitively established |
| Interference with live vaccines | IVIG contains passive antibodies that may interfere with MMR/varicella vaccine efficacy for several months |
| Underlying Cause | Long-Term Complications |
|---|---|
| G6PD deficiency | Recurrent haemolytic crises with future oxidant exposures (infections, drugs, foods); chronic haemolysis → pigmented gallstones; aplastic crises (parvovirus B19) |
| Hereditary spherocytosis | Chronic haemolytic anaemia; pigmented gallstones (50% of adults) [14]; aplastic crises; post-splenectomy overwhelming sepsis (OPSI) |
| Rh haemolytic disease | Late anaemia (persistent maternal anti-D destroying neonatal RBCs for weeks after birth → may need "top-up" transfusions); iron overload if multiple transfusions |
| Congenital hypothyroidism (if missed) | Cretinism: mental retardation, puffy face, deafness, mutism, protuberant abdomen, umbilical hernia; short stature and growth retardation in older children [8] |
| Galactosaemia | Cataracts (2 weeks), liver failure, E. coli sepsis, renal tubular acidosis, intellectual disability, ovarian failure in females — even with treatment, some cognitive effects may persist [23] |
| Biliary atresia (post-Kasai) | Recurrent cholangitis, progressive cirrhosis, portal hypertension, growth failure, need for liver transplantation [3][10][23] |
| Choledochal cyst | Cholangitis, ~2% risk of cholangiocarcinoma [3][23] |
| α₁-antitrypsin deficiency | Progressive cirrhosis in childhood; emphysema in adulthood (panacinar, lower lobes); HCC |
| Alagille syndrome | Chronic cholestasis with severe pruritus; cardiac disease (peripheral pulmonary stenosis — often the cause of mortality); renal tubular disorder; growth failure [3] |
| PFIC | Progressive cirrhosis requiring liver transplant; severe pruritus; hearing loss (PFIC1) [3] |
All neonates who have experienced significant hyperbilirubinaemia (particularly those who required phototherapy, exchange transfusion, or had evidence of haemolytic disease) should have:
| Follow-Up | Rationale |
|---|---|
| Auditory brainstem response (ABR) testing | SNHL is one of the earliest and sometimes ONLY manifestation of subclinical bilirubin neurotoxicity. Newborn hearing screening by otoacoustic emissions (OAE) alone may miss auditory neuropathy spectrum disorder (ANSD) — ABR is more sensitive. |
| Developmental surveillance | Monitor gross/fine motor milestones, language, cognition at standard intervals (6 weeks, 6 months, 12 months, 18 months, 2–3 years). Early intervention if concerns. |
| Growth monitoring | Especially important in cholestatic infants — plot weight, length, head circumference on age-appropriate growth charts. |
| Ophthalmology review | If galactosaemia (cataracts) or kernicterus (upward gaze palsy) suspected |
High Yield Summary — Complications of Neonatal Jaundice
- BIND is the feared complication of unconjugated hyperbilirubinaemia — free UCB crosses the BBB and is toxic to basal ganglia, brainstem auditory nuclei, and midbrain.
- ABE (acute bilirubin encephalopathy) is the acute, potentially reversible phase: lethargy → hypertonia → opisthotonos → seizures → death.
- Kernicterus is the chronic, irreversible phase: dystonic/choreoathetoid CP, SNHL, upward gaze palsy, dental dysplasia, intellectual disability.
- Kernicterus causes extrapyramidal (NOT spastic) CP — because it targets the basal ganglia.
- Conjugated bilirubin does NOT cause kernicterus — but signals serious hepatobiliary disease leading to fat-soluble vitamin deficiency (K → coagulopathy, D → rickets, E → haemolytic anaemia/neuropathy, A → night blindness), growth failure, progressive cirrhosis, portal hypertension, and need for liver transplantation.
- Biliary atresia → progressive cirrhosis even post-Kasai; recurrent cholangitis; most common indication for paediatric liver transplant.
- Choledochal cyst → cholangitis + ~2% cholangiocarcinoma risk.
- Treatment complications: phototherapy → dehydration, bronze baby syndrome (if conjugated); exchange transfusion → hypocalcaemia (most dangerous — QT prolongation), hyperkalaemia, thrombocytopenia, NEC, TA-GVHD (prevented by irradiated blood), mortality ~0.3–0.5%.
- All at-risk neonates need ABR testing (hearing), developmental surveillance, and growth monitoring.
Active Recall — Complications of Neonatal Jaundice
References
[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 46–49, 264–265) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 308, 313) [7] Unconjugated hyperbilirubinemia in newborns ≥35 weeks of gestation: Etiology and pathogenesis - UpToDate.pdf (p. 1) [8] Senior notes: Block A - I am losing weight and sweating all the time: causes of severe weight loss; thyrotoxicosis; hypothyroidism.pdf (p. 41) [9] Lecture slides: GC 146. A jaundiced child.pdf (pp. 2, 35, 48) [10] Senior notes: Maksim Surgery Notes.pdf (pp. 331, 333) [14] Senior notes: Ryan Ho Haemtology.pdf (p. 26) [15] Paediatrics in Review - Jaundice - Newborn to Age 2 Months.pdf (pp. 1, 7) [23] Senior notes: Maksim Paediatric Notes.pdf (pp. 85–86)
High Yield Summary
- Neonatal jaundice is the most common clinical condition in neonates — > 50% term, > 80% preterm, higher in Asians.
- Physiological jaundice is due to ↑ bilirubin production (high Hct, short RBC lifespan), ↓ conjugation (immature UDPGT), and ↑ enterohepatic circulation (sterile gut, low feeding volumes). It appears after 24h, peaks Day 3–5, and resolves by 2 weeks.
- Jaundice < 24 hours = ALWAYS pathological → think haemolysis (ABO, Rh, G6PD).
- G6PD deficiency is the most important enzymopathy in Hong Kong Chinese males (~4–6%) — screened at birth.
- Prolonged jaundice ( > 2 weeks term / > 3 weeks preterm) → MUST fractionate bilirubin (split conjugated vs unconjugated).
- Conjugated hyperbilirubinaemia is NEVER physiological → urgent investigation to exclude biliary atresia (surgical emergency — Kasai before 60 days ideal).
- Biliary atresia is the most common indication for paediatric liver transplant. Clues: persistent acholic stools, dark urine, hepatomegaly.
- BIND / Kernicterus is caused by unconjugated bilirubin crossing the BBB → damages basal ganglia → acute: opisthotonos, seizures; chronic: dystonic CP, SNHL, upward gaze palsy.
- Ceftriaxone is avoided in jaundiced/hypoalbuminaemic neonates (displaces bilirubin from albumin).
- Stool colour card is used in Hong Kong to screen for biliary atresia at the 1-month check.
High Yield Summary — Differential Diagnosis of Neonatal Jaundice
- First step: fractionate bilirubin → unconjugated vs conjugated. This dictates the entire differential.
- Second step: timing → early ( < 24h), normal (24h–2w), or prolonged ( > 2w term / > 3w preterm).
- Jaundice < 24 hours = haemolysis until proven otherwise (ABO > Rh > G6PD > membrane defects > congenital infection).
- Physiological jaundice is a diagnosis of EXCLUSION — must rule out pathological causes first.
- Breastfeeding jaundice ≠ breast milk jaundice: the former = inadequate intake (baby losing weight); the latter = breast milk substances inhibiting conjugation (baby thriving).
- Prolonged conjugated jaundice → MUST exclude biliary atresia — it is surgically treatable but time-critical (Kasai before 60 days). Acholic stools are the key clue.
- Biliary atresia vs neonatal hepatitis: persistent acholic stools + very high GGT + contracted GB on USG + no intestinal excretion on EHIDA → biliary atresia. Confirmed by operative cholangiogram (gold standard).
- HK-specific: G6PD screening at birth (cord blood), congenital hypothyroidism screening (cord TSH), stool colour card at 1-month check for biliary atresia, citrin deficiency is relatively common in Chinese.
- Conjugated bilirubin does NOT cause kernicterus — but signals serious hepatobiliary disease.
- UTI is an easily missed cause of neonatal jaundice — always check urine in any unexplained jaundice.
High Yield Summary — Diagnostic Approach to Neonatal Jaundice
- Step 1 — Screen: TcB (non-invasive) → if elevated, confirm with serum TSB → plot on Bhutani nomogram.
- Step 2 — Fractionate: Always determine conjugated vs unconjugated bilirubin. This is THE branch point.
- Step 3 — Unconjugated pathway: CBC, PBS, reticulocyte count, blood group + Coombs test, G6PD assay, LDH. Looking for haemolysis.
- Step 4 — Conjugated pathway (cholestasis): Full LFT (especially GGT), coagulation profile, albumin, glucose, USG abdomen, urine culture, TORCH screen, metabolic screen. Looking for biliary atresia, neonatal hepatitis, IEM.
- Step 5 — Biliary atresia workup: Fasting USG (contracted GB, triangular cord sign) → EHIDA scan (no intestinal excretion after phenobarbitone pre-treatment) → liver biopsy (bile duct proliferation, portal fibrosis) → operative cholangiogram (gold standard).
- Step 6 — Prolonged jaundice ( > 2 weeks term / > 3 weeks preterm): MUST fractionate bilirubin. If unconjugated → check TFT, urine culture, feeding adequacy. If conjugated → cholestasis pathway (as above).
- Physiological jaundice = diagnosis of exclusion. Unconjugated only, normal enzymes, no haemolysis, well baby, resolves by 2 weeks.
- Conjugated hyperbilirubinaemia is NEVER physiological → always warrants urgent investigation.
- In HK: cord blood G6PD screen (males), cord TSH screen, stool colour card at 1 month.
High Yield Summary — Management of Neonatal Jaundice
- Unconjugated NNJ: Optimise feeding → Phototherapy (blue-green light, 460–490 nm, converts UCB to lumirubin) → IVIG (for isoimmune haemolysis) → Exchange transfusion (double-volume, last resort).
- Phototherapy thresholds are based on age-in-hours, gestational age, and neurotoxicity risk factors (AAP 2022 nomogram).
- Phototherapy is contraindicated in conjugated hyperbilirubinaemia — causes bronze baby syndrome and delays real diagnosis.
- Exchange transfusion removes ~85% of antibody-coated RBCs and ~50% of intravascular bilirubin. Use irradiated, CMV-negative, fresh blood. Complications: electrolyte shifts (hypocalcaemia!), infection, NEC, mortality ~0.3–0.5%.
- Conjugated NNJ: NO phototherapy. Nutritional support (MCT formula + fat-soluble vitamins A, D, E, K) for ALL. UDCA for intrahepatic cholestasis (contraindicated in extrahepatic obstruction until bile flow restored).
- Biliary atresia: Kasai portoenterostomy ideally before 60 days → post-op UDCA + prophylactic antibiotics → liver transplant if Kasai fails. BA is the most common indication for paediatric LT.
- Galactosaemia: Immediate dietary galactose elimination (soy formula).
- G6PD deficiency: Avoidance of triggers + supportive treatment.
- Always treat the underlying cause alongside managing the bilirubin level.
- Family-centred care: Explain treatment, educate on stool colour card, support breastfeeding, genetic counselling where appropriate.
High Yield Summary — Complications of Neonatal Jaundice
- BIND is the feared complication of unconjugated hyperbilirubinaemia — free UCB crosses the BBB and is toxic to basal ganglia, brainstem auditory nuclei, and midbrain.
- ABE (acute bilirubin encephalopathy) is the acute, potentially reversible phase: lethargy → hypertonia → opisthotonos → seizures → death.
- Kernicterus is the chronic, irreversible phase: dystonic/choreoathetoid CP, SNHL, upward gaze palsy, dental dysplasia, intellectual disability.
- Kernicterus causes extrapyramidal (NOT spastic) CP — because it targets the basal ganglia.
- Conjugated bilirubin does NOT cause kernicterus — but signals serious hepatobiliary disease leading to fat-soluble vitamin deficiency (K → coagulopathy, D → rickets, E → haemolytic anaemia/neuropathy, A → night blindness), growth failure, progressive cirrhosis, portal hypertension, and need for liver transplantation.
- Biliary atresia → progressive cirrhosis even post-Kasai; recurrent cholangitis; most common indication for paediatric liver transplant.
- Choledochal cyst → cholangitis + ~2% cholangiocarcinoma risk.
- Treatment complications: phototherapy → dehydration, bronze baby syndrome (if conjugated); exchange transfusion → hypocalcaemia (most dangerous — QT prolongation), hyperkalaemia, thrombocytopenia, NEC, TA-GVHD (prevented by irradiated blood), mortality ~0.3–0.5%.
- All at-risk neonates need ABR testing (hearing), developmental surveillance, and growth monitoring.
Bronchiolitis
Bronchiolitis is an acute viral lower respiratory tract infection, most commonly caused by respiratory syncytial virus (RSV), predominantly affecting infants and children under 2 years of age, characterized by inflammation and obstruction of the small airways (bronchioles) leading to wheezing, tachypnoea, and respiratory distress.
Primary Immunodeficiency
Primary immunodeficiency comprises a group of inherited disorders, typically presenting in infancy or early childhood, in which one or more components of the immune system are absent or dysfunctional, leading to increased susceptibility to recurrent, severe, or unusual infections.